
==== Front
Commun Eng
Commun Eng
Communications Engineering
2731-3395
Nature Publishing Group UK London

39227652
276
10.1038/s44172-024-00276-3
Review Article
Multidisciplinary approaches in electronic nicotine delivery systems pulmonary toxicology: emergence of living and non-living bioinspired engineered systems
http://orcid.org/0000-0001-9117-3959
Benam Kambez H. kambez.benam@pitt.edu

123
1 https://ror.org/01an3r305 grid.21925.3d 0000 0004 1936 9000 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA USA
2 https://ror.org/01an3r305 grid.21925.3d 0000 0004 1936 9000 Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA USA
3 https://ror.org/01an3r305 grid.21925.3d 0000 0004 1936 9000 Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA USA
3 9 2024
3 9 2024
2024
3 12326 2 2024
27 8 2024
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Technology-based platforms offer crucial support for regulatory agencies in overseeing tobacco products to enhance public health protection. The use of electronic nicotine delivery systems (ENDS), such as electronic cigarettes, has surged exponentially over the past decade. However, the understanding of the impact of ENDS on lung health remains incomplete due to scarcity of physiologically relevant technologies for evaluating their toxicity. This review examines the societal and public health impacts of ENDS, prevalent preclinical approaches in pulmonary space, and the application of emerging Organ-on-Chip technologies and bioinspired robotics for assessing ENDS respiratory toxicity. It highlights challenges in ENDS inhalation toxicology and the value of multidisciplinary bioengineering approaches for generating reliable, human-relevant regulatory data at an accelerated pace.

Kambez Benam reviews preclinical approaches to assess lung health impacts of e-cigarettes, highlighting limitations of current strategies in capturing 3D lung architecture and inhalation mechanics. The review article emphasizes the promise of Organs-on-Chips and Bioinspired Robotics.

Subject terms

Lab-on-a-chip
Tissue engineering
https://doi.org/10.13039/100000050 U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL159494 Benam Kambez H. https://doi.org/10.13039/100000070 U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB) U01EB029085 Benam Kambez H. https://doi.org/10.13039/100007921 University of Pittsburgh (Pitt) PACCSM Benam Kambez H. issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The rapid development and proliferation of electronic nicotine delivery systems (ENDS) over the past two decades have considerably impacted society and health, both in the United States and globally. ENDS encompass a wide variety of products, including vapes, vaporizers, vape pens, hookah pens, electronic cigarettes (ECs), e-cigars, and e-pipes. The widespread adoption of these devices is driven by their accessibility and the customizable nature of e-liquids. Among these products, ECs have become the most widely used, which particularly concerning because they appeal to youth and young adults who have never smoked traditional cigarettes.

A key driver behind the rapid adoption of ENDS is the perception that they are a safer alternative to traditional combustible cigarettes1. This perception is largely fueled by marketing strategies that emphasize the absence of tar and other harmful combustion by-products; however, ENDS are not harmless2–5. The ability to customize e-liquids with various flavors and nicotine concentrations has made ENDS attractive to younger populations. Flavors such as fruit, candy, dessert, mint, and menthol are especially appealing to adolescents and young adults6, contributing to the initiation of vaping among these groups.

The societal impact of ENDS is multifaceted. There is potential for harm reduction among adult smokers who switch entirely from combustible cigarettes to ENDS, potentially lowering their exposure to harmful chemicals. However, the widespread use of ENDS among non-smoking youth and young adults poses substantial public health challenges. The increasing prevalence of nicotine addiction in these demographics is notably alarming, as it can lead to long-term health consequences and an increased likelihood of transitioning to traditional cigarette smoking. Furthermore, the accessibility of ENDS products through online and retail stores as well as social sourcing has facilitated their adoption7–10. Despite regulatory efforts to restrict sales to minors, many young users still find ways to purchase these products. This accessibility, combined with aggressive marketing and social media influence, has considerably contributed to the normalization of vaping in youth culture2,5,8,10.

Context and challenges

Epidemiological data and trends

Recent data indicate that ECs were the most commonly used tobacco product among middle and high school students in the U.S. in 2022 and 20236. In 2023 alone, 22.2% of this population reported ever using any tobacco product6. Similarly, a cross-sectional study involving more than 414,000 participants surveyed via the 2021 Behavioral Risk Factor Surveillance System (BRFSS) in the U.S. revealed a vaping incidence of 18.3% among young adults aged 18–24 years11. Among those reporting current EC use, more than 20% indicated no prior use of combustible cigarettes11. These epidemiological findings underscore the extensive and unintended impact of the ENDS. The popularity of vaping devices especially among adolescents increases the risk of nicotine addiction and potential long-term health consequences. This reach of ENDS is beyond its potential as a less harmful alternative to traditional cigarettes, highlighting the need for targeted regulation and public health interventions to mitigate adverse effects.

Pulmonary and cardiovascular health impacts

Emerging research has revealed a range of negative health effects associated with the use of ENDS. An analysis of surveys and electronic health records from over 175,000 participants from All of Us Research Program—a large national study led by the U.S. National Institutes of Health, Bene-Alhasan et al. revealed that individuals who used ECs were 19% more likely to develop heart failure than those who had never used ECs12. Similarly, Mohammadi and colleagues demonstrated that chronic EC use significantly impairs vascular function13. Their findings showed that chronic EC users exhibited lower brachial artery flow-mediated dilation than nonusers13. Additionally, compared with serum from nonusers, serum from EC users has been shown to reduce vascular endothelial growth factor-stimulated nitric oxide secretion from endothelial cells13. The study also identified a significant increase in the circulating levels of endothelial cell adhesion molecules and inflammatory markers, including S100 calcium binding protein A8, high mobility group box 1, interferon β, soluble intracellular adhesion molecule 1, von Willebrand factor, and myeloperoxidase, in EC users13. These findings highlight the harmful effects of chronic EC use on vascular endothelial function.

In pulmonary medicine, the use of ECs has been linked to an increased incidence of respiratory symptoms in adolescents and young adults14–16. Tackett et al. evaluated a sample of over 1500 U.S. high school students, with a mean age of 17.3 years, over four separate occasions (2014, 2015, 2017, and 2018). The study found that past 30-day EC use increased the odds of wheezing (odds ratio [OR] 1.41), bronchitic symptoms (OR 1.55), and shortness of breath (OR 1.48) after adjusting for various factors such as study timepoint, age, sex, race, lifetime asthma diagnosis, parental education, current cigarette use, cannabis use, and secondhand exposure to ECs, cigarettes, and cannabis14. McConnell and colleagues reported similar results in their analysis of 2,086 participants from the Southern California Children’s Health Study. They found that the risk of bronchitic symptoms was greater among past (OR 1.71) and current (OR 1.41) EC users, based on the questionnaires completed by 11th and 12th-grade students15. Out of the total sample, 502 participants had ever used ECs, with 301 being past users and 201 being current users15. Internationally, Alnajem et al. conducted a cross-sectional study involving 1345 high school students aged 16–19 years in Kuwait. The study revealed that 27.4% of the participants reported EC use16. Compared with nonusers, those with no history of cigarette smoking had an increased prevalence of wheezing (adjusted prevalence ratio [PR] 1.54) and asthma symptoms (adjusted PR 1.85)16. These studies collectively highlight important respiratory risks associated with EC use among adolescents and young adults, emphasizing the need for increased awareness and regulatory measures to mitigate these health impacts.

Chemical composition and toxicity of e-liquids

E-liquids, also known as vape liquids, are liquids within an ENDS that, when heated, transform into inhalable aerosols and deliver nicotine, flavorings, and/or other ingredients to vaping device users without the combustion process associated with traditional tobacco products. The primary constituents of any e-liquid are propylene glycol (PG) and vegetable glycerin (VG). PG and VG are also referred to as EC humectants, solvent carriers, or vaporizing solvents; they lead to aerosol production, which simulates combustible tobacco cigarette smoke (CS)17.

Multiple studies have revealed the toxicity of PG and VG18–23. PG, which when heated, accounts for ~30–95% of an EC liquid by volume24–27, can generate toxic respiratory chemicals, including diacetyl, formaldehyde, and methylglyoxal18,19. Komura et al. reported that exposure of primary healthy and chronic obstructive pulmonary disease (COPD)-derived human small airway epithelial cells to 4% PG significantly inhibited cell proliferation and viability, induced apoptosis, led to DNA damage, and caused cell cycle arrest in vitro20. Similarly, PG:VG negatively impacts the viability of human airway smooth muscle cells21. In another report, Woodall and colleagues showed that treating primary human bronchial epithelial cells with a PG or PG:VG mixture for as little as 30 min inhibited glucose transport and metabolism, reduced cell height, lowered barrier function, and increased airway surface liquid height22.

Case studies: EVALI and diacetyl exposure

The findings discussed above clearly indicate the toxic potential of e-liquid components and their vaporized aerosols. However, given the vast diversity of flavorings, nicotine concentrations and types, and other chemicals (many of which are proprietary) that can be added to PG:VG mixtures, along with the variety of PG:VG ratios that can be prepared, numerous e-liquids can potentially be obtained. This creates a new layer of complexity and uncertainty when predicting the potential toxicity of any given e-liquid. Muthumalage et al. showed that the treatment of human monocytic cell lines with flavoring chemicals and nicotine-free flavored e-liquids caused cytotoxicity and induced secretion of the pro-inflammatory chemokine IL8 in vitro28. In 2014 alone, more than 7000 unique e-liquid flavorings were commercially available online29, and the range of flavorings has grown considerably since then. Therefore, there is an urgent need for rapid evaluation of emerging ENDS products to determine their potential pulmonary toxicity.

This need is exemplified by instances in which seemingly safe compounds are mixed and matched in e-liquids by users, but the exposure to aerosols of such ENDS has led to unexpectedly high morbidity and/or mortality. For instance, between 2019 and 2020, the United States reported 2807 cases of e-cigarette, or vaping, product use-associated lung injury (EVALI), which led to 68 deaths as of October 2020, representing ~2.4% mortality rate30,31. Initial analyses of bronchoalveolar lavage fluid (BALF) identified vitamin E acetate (VEA) in 48 out of 51 patients with EVALI across 16 states32. Following a nationwide investigation, the U.S. Centers for Disease Control and Prevention (CDC) announced that the addition of VEA to e-liquids is strongly linked with the EVALI epidemic33. Systematic studies revealed that the majority of EVALI patients required hospitalization, with around 95% needing inpatient care, and ~27% of those admitted requiring intubation31. Additionally, mortality rates were higher among older patients and those with pre-existing conditions such as cardiac disease, asthma, or mental health issues34,35. Moreover, a 12-month follow-up of EVALI survivors showed that 39% of patients had cognitive impairment, whereas 48% experienced respiratory limitations36.

Another example of a chemical added to vaping liquids that was initially considered safe is diacetyl, also known as 2,3-butanedione. This substance is a member of a class of organic compounds called diketones and is known for imparting a buttery flavor37. Diacetyl occurs naturally in some foods and is also used as a synthetic flavoring agent in products such as butter, cocoa, coffee, and dairy products37. While it has been approved for ingestion and considered safe by the National Institute for Occupational Safety and Health (NIOSH)38 and the Flavor and Extract Manufacturers Association (FEMA) under FEMA GRAS No. 2370, inhalation of diacetyl is a different matter. Workers exposed to diacetyl-containing flavorings have reported an excessive decline in forced expiratory volume in one second (FEV1), which indicates respiratory impairment39. Additionally, diacetyl has been linked to higher risk of developing bronchiolitis obliterans, COPD, and other severe pulmonary conditions40–42. This condition was first identified in workers at popcorn factories who were exposed to elevated levels of diacetyl used in artificial butter flavoring. Unfortunately, despite its harmful respiratory effects, when inhaled, several studies have shown that diacetyl is one of the most prevalent chemicals in EC vapors37,43,44.

Global regulatory disparities and challenges

Global disparities in the regulation and public perception of ENDS add further complexities to the increasing popularity and utilization of these products. Divergent approaches, ranging from stringent regulations in certain countries to more permissive attitudes elsewhere, underscore the imperative for international cooperation and standardized guidelines to address the multifaceted challenges posed by ENDS effectively. For instance, the World Health Organization recently reported substantial discrepancies in regulatory frameworks across nations. As of July 2023, shockingly, 88 countries lacked a minimum age requirement for the purchase of vaping devices, while an alarming 74 countries, predominantly African countries alongside Mongolia, Pakistan, and Colombia, had no established regulations safeguarding public health against these potentially harmful products45. In contrast, 34 countries, including Iran, India, Thailand, and Brazil, implemented outright bans on ENDS45. These disparities highlight the need for concerted global efforts to establish cohesive regulatory frameworks that prioritize public health and safety. Harmonizing regulations and fostering collaboration among nations can help mitigate the adverse effects of ENDS and promote more consistent and effective measures to address their proliferation and use worldwide.

As discussed above, the widespread use of ENDS has led to substantial societal and health implications. The varied ENDS products, including vapes and ECs, appeal to a broad demographic, including youth, raising public health concerns. The negative health effects, such as cardiovascular and respiratory issues, underscore the urgent need for regulatory frameworks. The EVALI epidemic and the toxicity of compounds such as VEA and diacetyl highlight the severe risks associated with ENDS. Given these complexities, it is crucial to utilize advanced and human-relevant preclinical models to study the inhalation toxicology of ENDS comprehensively. Figure 1 and Table 1 provide an overview of the diverse models discussed in this article. These models offer varying degrees of physiological relevance and complexity, helping researchers understand the multifaceted effects of ENDS exposure and developing strategies for public health protection.Fig. 1 Evolving Landscape of Preclinical Tools Used for Toxicological Assessment of Electronic Nicotine Delivery Systems.

a Electronic nicotine delivery systems (ENDS) are proliferating swiftly, with a wide array of e-liquid ingredients and device functionalities, presenting considerable challenges in assessing their potential pulmonary toxicity. Traditional methodologies predominantly include two-dimensional (2D) cell culture models that employ either cell lines or undifferentiated primary human lung cells (b), as well as static three-dimensional (3D) in vitro models such as air-liquid interface (ALI) cultures using primary human airway epithelial cells in transwell inserts (TWIs) (c), microtome-assisted precision cut lung slices (PCLS) (d), laboratory animals, notably rodents (e), and, rarely, lung spheroids and organoids (f). Complementary techniques involve in silico modeling (g) and physicochemical analytical methods such as quartz crystal microbalance (QCM), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) spectroscopy (h, i). Emerging bioengineered technologies, such as Lung-on-a-Chip living devices (j) and the bioinspired non-living robotic platform Human Vaping Mimetic Real-Time Particle Analyzer (HUMITIPAA) (k), offer new opportunities to overcome certain limitations of existing tools, enhance human and clinical relevance, and expedite toxicity evaluation. Images in (j, k) were reproduced from ref. 87. and ref. 138, respectively. a–g, i Were fully or in part created using BioRender.com, and (j, k) were reproduced with permission from ref. 87 and ref. 138.

Table 1 Preclinical Platforms for ENDS Inhalation Toxicology. Various systems, living and non-living, bioengineered and non-bioengineered, reviewed in this article

System Classification	Components	Characteristics (Pros and Cons)	Provided Biological Information	Application Examples	
2D and 3D Static Cell Culture Models	Human lung epithelial cell lines (e.g., Beas-2B); TWI models of primary hAEpCs	Pros: 2D Cultures: easy to culture, amenable for medium-to-high throughput testing. TWIs: recreation of in vivo-seen differentiated airway epithelium.

Cons: 2D Cultures: lack differentiation into mucociliated airway epithelium, do not capture inter-individual variability. TWIs: lack dynamic interaction between lung epithelium and systemic immune system, limited multicellularity, absence of blood-like fluidic flow and physiological vascular shear, lack sub-epithelial extracellular matrix.

	Cytotoxicity, inflammatory response, oxidative stress.	BEAS-2B cells to investigate cytotoxicity and inflammatory response to EC aerosols.	
Lung Spheroids and Organoids	3D structures mimicking airway and alveoli derived from lung cells, iPSCs or tumor cells	Pros: More closely mimic tissue architecture and cellular interactions.

Cons: Lack vasculature, ALI, hard to control cell ratio and aggregate size, inability to recapitulate dynamic mechanical forces with blood and air flows.

	Differentiation into various lung cell types, cellular interactions.	Bronchial spheroids (derived from BEAS-2B cells) to study response to diesel exhaust particles.	
Precision Cut Lung Slices (PCLS)	Uniform whole lung sections (150–500 µm thick)	Pros: Mimic cellular and architectural complexity of lung.

Cons: Limited viability, lack vascular circulation, high variability, absence of epithelial ALI.

	Tissue-level responses, antiviral responses.	Human PCLS to study effects of vaping extract and IAV infection.	
Animal Models	Mostly mice (e.g., C57BL/6) or rats (e.g., Sprague Dawley)	Pros: Systemic effects, multi-organ responses.

Cons: Ethical concerns, interspecies differences, time-consuming.

	Pulmonary and systemic inflammation, immune responses, toxicological outcomes.	Mice exposed to EC aerosols to study inflammatory and immune responses.	
Organs-on-Chips	Microfluidic devices populated with human cells (e.g., Lung Small Airway-on-a-Chip, Vasculature-on-a-Chip)	Pros: Reproduce tissue‒tissue interfaces, mechanical cues, vascular perfusion.

Cons: Low throughput, costly, lack certain tissue complexities.

	Lung pathophysiology, cytokine secretion, immune cell recruitment, therapeutic responses.	Human Lung Small Airway-on-a-Chip to study response to EC aerosols under physiologically relevant breathing conditions.	
Computational Approaches	QSAR models, CFPD-PBTK models	Pros: Predict toxicity and particle deposition, reduce animal usage.

Cons: Require high-quality data, need validation, may not account for all physical and chemical interactions.

	Predictive toxicology, pharmacokinetics, molecular interactions.	QSAR models to predict inhalation toxicity of ENDS chemicals.	
Physico-chemical Analyses	QCM, Cascade Impactors, NMR, GC-MS	Pros: Provide detailed chemical composition and physical characteristics.

Cons: Often terminal endpoints, not real-time, scalability issues.

	Particle size distribution, chemical composition, toxic compound identification.	QCM to quantify particulate mass from aerosols, GC-MS for chemical analysis of e-liquids.	
Bioinspired Robotics	HUMITIPAA	Pros: Simulate human vaping behavior and respiration mechanics, measure real-time particle inhalation.

Cons: Need expansion for measuring nanoparticles, association with biological impact needed.

	Real-time particle size distribution, inhaled particle quantity, inhalation dynamics.	HUMITIPAA to assess inhaled particle profiles (quantity and size distribution) from ECs containing VEA or menthol.	
Column titles are noted in bold.

ENDS: electronic nicotine delivery systems, TWI transwell insert, ALI air-liquid interface, EC electronic cigarette, hAEpCs human airway epithelial cells, 2D two-dimensional, 3D three-dimensional, iPSCs induced pluripotent stem cells, PCLS precision-cut lung slices, QSAR quantitative structure-activity relationship, CFPD-PBTK computational fluid-particle dynamics-physiologically based toxicokinetic numerical model, QCM quartz crystal microbalance, NMR nuclear magnetic resonance spectroscopy, GC-MS gas chromatography-mass spectrometry, HUMITIPAA Human Vaping Mimetic Real-Time Particle Analyzer, VEA vitamin E acetate.

Existing preclinical living models for the pulmonary toxicological assessment of ENDS

The impact of vaping has been predominantly studied via models of the lung due to inhaled exposure to EC vapors. These studies have provided meaningful insights into the respiratory effects of vaping, including inflammation, impaired lung function, and increased risk of respiratory diseases. However, there are also preclinical and clinical reports that have examined the effects of vaping on other organ systems, indicating potential broader systemic health risks12,13,46–53. Despite these important findings, the focus of this paper is confined to the pulmonary impacts of vaping.

A critical aspect of addressing the societal and health impacts of emerging ENDS and regulatory needs is the development of new preclinical tools. These tools should be human-centric, physiologically and clinically relevant, and capable of rapidly generating data for toxicological assessments. Traditional methods often struggle to keep pace with the dynamic landscape of emerging products, necessitating innovative research models that accurately simulate human responses to ENDS exposure.

2D and 3D static cell culture models

Several two-dimensional (2D) and three-dimensional (3D) static cell culture models have been applied to evaluate the pulmonary toxicity of ENDS. These models often involve human lung epithelial cell lines or primary cells cultured either on traditional plates or on the porous membranes of transwell inserts (TWIs)23,54–56. For instance, Anthérieu et al. utilized the human bronchial epithelial cell line Beas-2B at an air-liquid interface (ALI) to compare the toxicity of EC vapors against CS54. Similarly, Sinha and colleagues used Beas-2B cells to investigate the cytotoxicity and inflammatory response to EC aerosols55. While these studies offer valuable insights, due to their specific origins and characteristics, into the toxicological effects of ENDS and can potentially be performed in a medium- to high-throughput manner, they are limited by the virtue of using cell lines. For example, Beas-2B cells, though non-cancerous, have been immortalized by viral infection to express the SV40 T antigen and lack the ability to differentiate well into mucociliated bronchial epithelium57. Additionally, these cells exhibit surface marker expression profiles and osteogenic and adipogenic differentiation potentials similar to those of human umbilical cord-derived mesenchymal stem cells58.

In contrast, the differentiation of primary human airway epithelial cells (hAEpCs) into ciliated epithelia under ALI provides a histologically more relevant model system for analyzing ENDS-related respiratory toxicity. Manna et al. exposed mucociliated hAEpCs cultured in TWIs to EC vapors and assessed changes in cellular populations and the secretion of immunomodulatory cytokines56. The use of differentiated hAEpCs enables researchers to replicate various epithelial subtypes, including ciliated cells, mucin-producing goblet cells, Club cells, and basal cells, mimicking the pseudostratified columnar epithelium of the human airway. However, several limitations affect this approach: (1) inability to replicate the dynamic interaction between the lung epithelium and the systemic immune system, including the recruitment and activation of circulating leukocytes; (2) limited multicellularity, as most models only reconstitute the epithelium in vitro; (3) lack of blood-like fluidic flow, resulting in the absence of physiological vascular shear and dynamic endothelial cell–immune cell interactions in these model systems when epithelium is in co-culture with endothelial cells; and (4) absence of a physiologically relevant and thick sub-epithelial extracellular matrix (ECM). Furthermore, at best, hAEpC ALI cultures are exposed to vertically delivered puffs of EC aerosols under static conditions, whereas human ENDS users typically exhibit characteristic patterns of puff durations, puff volumes, and inter-puff intervals (referred to as vaping topography) combined with breathing mechanics, resulting in dynamic exposure to EC aerosols under conditions of inhale-exhale airflow that apply horizontal shear forces across the airway epithelium59,60.

Lung spheroids and organoids

Spheroids and organoids derived from lung cells constitute another potential culture system for pulmonary toxicology studies. Spheroids are 3D sphere-like clusters of cells that can self-assemble from single-cell suspensions61–67. They are typically derived from tumor cells or immortalized lines (e.g., A549)62, primary cells such as outgrowth progenitor cells from lung tissue explants or cells obtained from transbronchial lung biopsies63–65, or induced pluripotent stem cells (iPSCs)66,67. Lung spheroids can mimic the alveoli and airway epithelium. Organoids, on the other hand, are more complex 3D structures that arise from stem or progenitor cells, and are capable of self-organizing into miniaturized and simplified versions of organs such as alveolar-like sacs and bronchiole-like, airway structures61,68,69. Compared with spheroids, lung organoids exhibit self‐renewal capacity and consist of more than one cell type or tissue. Additionally, they exhibit long-term viability and depend on intrinsic developmental processes rather than solely on cell-cell adhesions to form tissue- and organ-like microarchitectures61.

The application of lung organoids and spheroids to study the toxicity of ENDS has been very limited. As of July 2024, only one study has utilized bronchial spheroids derived from Beas-2B cells to investigate the effects of diesel exhaust particles70. This study revealed that exposure to diesel exhaust particles significantly impacts the viability and function of bronchial spheroids, leading to increased production of pro-inflammatory cytokines and oxidative stress markers.

Despite their potential, there are limitations to organoids and spheroids. Spheroids, while valuable, lack the complexity of full organ systems and may not fully recapitulate the lung microenvironment. They also lack vasculature and ALI, which are essential features for accurately simulating lung physiology. Furthermore, controlling cell ratios and aggregate sizes in spheroid cultures can be challenging, leading to variability in experimental outcomes. Organoids, though more complex, can exhibit variability in size and cellular composition, and their generation and maintenance require specialized techniques and expertise. They lack several key organ features such as vascularization, and it can be challenging to obtain fully differentiated lung cell types. Importantly, neither model can fully replicate the dynamic mechanical forces with blood and air flows experienced in vivo.

Precision-cut lung slices

Precision-cut lung slices (PCLS)71–74, uniform sections of the lung measuring 150–500 µm in thickness, have emerged as an organotypic ex vivo model that addresses the limitations of cell lines and primary human lung epithelial cell ALI cultures. In the context of ENDS toxicology, few studies have been performed using PCLS. Crue et al. exposed human PCLS from a single donor to vaping extract with or without influenza A virus (IAV) infection, followed by single-cell RNA sequencing to analyze changes in host antiviral and pro-inflammatory responses75. The vaping extract was prepared by passing vapors from a commercially available EC through tissue culture medium. Similarly, the same research group treated PCLS obtained from the lungs of five non-smoking healthy human donors with e-liquid and IAV to investigate the viral load and immune response76. PCLS obtained from animals, such as chicks (Gallus gallus)77 and laboratory mice (strain C57BL/6)78, have also been utilized for evaluating EC toxicity. Despite their ability to closely mimic the cellular and architectural complexity of the (human or animal) lung, PCLS has several drawbacks. These limitations include relatively low viability in culture; typically necessitating experimentation within 5–10 days of slicing; inability to recreate physiological ALI and breathing and exposure to ENDS aerosols under rhythmic inhalation airflow; lack of vascular circulation; inability to recreate dynamic intercellular interactions between circulating immune cells and vascular endothelial cells; considerable heterogeneity in cellular composition and responses to stimulation between slices obtained from different locations of the same donor lung or single lobe, as well as across different donors; limited availability of human lungs for slicing; and challenges in standardization and automation owing to manual processing and handling, apart from slicing via a microtome.

Animal models

To complement the in vitro and ex vivo experimental approaches discussed above, researchers have turned to animal models79–83. In this context, laboratory mice and rats have been the most extensively utilized in vivo models79–81. For example, Ha et al. conducted a study in which wild-type C57BL/6 mice were exposed to EC aerosols for 4 months and evaluated for inflammatory and immune responses in the larynx and compared them to those in mice exposed to CS79. In another study, mice were acutely challenged with aerosols generated from a PG:VG e-liquid supplemented with VEA, and the total number of leukocytes infiltrating the lungs, as well as the levels of VEA and albumin in the BALF, were analyzed80. Similarly, Rau and colleagues exposed Sprague Dawley rats to EC vapors for 4 weeks to investigate the toxic microcirculatory effects of exposure81.

Animal models offer insights into the local (pulmonary) and systemic effects of ENDS aerosols, as well as their impact on other organ systems. However, ethical considerations on the use of animals in biomedical research and interspecies differences limit the extrapolation of findings to humans. For instance, the microscopic structure of the lungs, airway branching, cellular distribution, and immune system functioning differ substantially between rodents and humans84–87 (e.g., neutrophils constitute 10–25% of circulating leukocytes in mice vs. 50–70% in humans85,87). Additionally, the number of non-ciliated Club-like cells in the small airways of rats and mice is ~10-fold greater than that in humans, and goblet cells are almost absent in the membranous bronchioles of mice and rats86. Moreover, rodents are obligate nose breathers with intricate and highly developed nasal turbinates that lead to different particulate deposition patterns than humans88. Furthermore, replicating human-relevant underlying conditions, such as former smoking status or co-morbidities such as idiopathic pulmonary fibrosis (IPF), COPD airway disease, or severe corticosteroid-resistant asthma, can be difficult, if not impossible. Additionally, observing the emergence of an EC-induced phenotype of interest in animal models can be a time-consuming process, often spanning several weeks to months.

Organ-on-a-Chip models of inhaled exposure to ENDS aerosols

Organs-on-Chips87,89–102, commonly referred to as microphysiological systems (MPS), are microfluidic cell culture devices designed to mimic the structure and function of human tissues and organs at a miniature scale. These experimental research tools predominantly consist of a transparent, flexible, and gas-permeable polymer, like polydimethylsiloxane (PDMS), housing hollow microfluidic channels lined with living human cells and/or chambers filled with cell-free or cell-laden hydrogels. By recapitulating the multicellular architectures, tissue‒tissue interfaces, chemical gradients, mechanical cues, and vascular perfusion of natural organs, these devices reproduce levels of tissue and organ functionality that are not possible with conventional 2D or 3D culture systems. They also enable high-resolution, real-time imaging and in vitro analysis of the biochemical, genetic, and metabolic activities of living human cells in a functional human tissue and organ context. Organs-on-Chips offer a platform for studying disease mechanisms, drug toxicity, and efficacy as well as inhalation toxicology in a more physiologically relevant context. Moreover, they can be interconnected to create multi-organ systems, allowing researchers to study organ‒organ interactions and the systemic effects of drugs and toxins. As such, Organs-on-Chips hold remarkable potential for advancing biomedical research, including tobacco-related toxicology, and provide an opportunity to address limitations of existing preclinical living lung models of ENDS exposure.

Lung Small Airway-on-a-Chip

The application of Organs-on-Chips technology in the toxicology of ENDS is still emerging. Benam et al. pioneered this approach by developing an all-primary Human Lung Small Airway-on-a-Chip87. This biodevice integrated two channels: an airway channel coated with human-derived mucociliary bronchiolar epithelium maintained at an ALI and a vascular channel that simulates post-capillary venules lined with human microvascular endothelium under fluid flow. These channels were separated by a porous membrane that allowed nutrient exchange. The biodevice enabled the investigators to replicate and analyze lung airway pathophysiology at the organ level in vitro, including modeling disease-relevant human lung airway inflammation, detecting synergistic effects of the lung endothelium and epithelium on cytokine secretion, and quantifying the recruitment of circulating immune cells in response to activation by the viral mimic poly I:C, demonstrating similar trends in biological responses among chips fabricated with cells from the same donor population, identifying a new biomarker of disease exacerbation induced by viral infection, and measuring therapeutic responses to anti-inflammatory drugs that inhibit cytokine-induced recruitment of circulating neutrophils under flow87.

Breathing-Smoking/Vaping Human Lung-on-a-Chip

In a follow-up study, the same research team expanded on this model and created a modular and microfluidically integrated platform that allowed in vitro analysis of the effects of whole cigarette smoke and EC aerosols delivered under physiologically relevant flow conditions that mimic breathing on the pathophysiology of differentiated human mucociliated bronchiolar epithelium91. This platform, referred to as the Breathing-Smoking/Vaping Human Lung-on-a-Chip, consisted of the Lung Small Airway-on-a-Chip—the living conducting airway tissue to be exposed to inhaled smoke/vapors; a micro-respirator that mimicked ribcage and the diaphragm to reproduce breathing mechanics and patterns; a microfluidically compatible fresh whole CS and EC vapor generator; and control software that represented the brain of a human smoker/vaping device user to recreate smoking/vaping topography parameters91,96. The motive for developing such a system was that smoking represents a major risk factor for COPD and is a leading non-infectious cause of exacerbations; however, characterizing smoke-induced injury responses under physiological breathing conditions in humans is challenging due to patient-to-patient variability. By applying multi-omics analyses, including gene microarrays, this work identified novel biomarkers for COPD patients who might exhibit greater sensitivity to smoke and novel therapeutic target candidates. In addition, the authors used this platform to expose mucociliated bronchiolar epithelia to aerosols of a first-generation disposable EC and studied the induction of oxidative stress and changes in ciliary beating frequency91.

Vasculature-on-a-Chip

In another study, Ohashi and colleagues used a commercially available Vasculature-on-a-Chip model to study the effects of aerosols from heated tobacco products (HTPs) on macrophage adhesion, endothelial expression of the surface intracellular cell adhesion molecule 1, and secretion of pro-inflammatory cytokines103. The device consisted of two channels, one of which was used for seeding primary human coronary artery endothelial cells and the other for loading a porcine collagen I-based hydrogel. THP-1 cells were used as macrophages in this study.

Applications beyond inhalation toxicology

Notably, MPS have been applied successfully in several other fields. In drug development and safety testing, Liver-on-a-Chip models predict human hepatotoxicity and detect cross-species toxicological risks104,105. In cancer research, Tumor-on-a-Chip models replicate tumor microenvironments, aiding in the discovery of anti-cancer drugs106–110. Neurological diseases have benefited from Brain-on-a-Chip and Blood Brain Barrier-on-a-Chip models, facilitating studies on neurodegenerative diseases like Alzheimer’s and Parkinson’s, leading to new drug targets and therapeutic candidates111–116. Additionally, cardiovascular research has utilized Heart-on-a-Chip models to study cardiac physiology, identify cardiotoxic compounds, and ensure safer therapeutic options117–120.

Challenges and future directions

The human Lung Small Airway-on-a-Chip87 overcomes several limitations of the most advanced lung airway preclinical models that are currently used, namely, TWI ALI culture and PCLS. These include the reproduction of multicellular co-culture of mucociliated hAEpCs with lung microvascular endothelial cells; the introduction of freshly generated ENDS aerosols under rhythmic breathing airflow without disrupting ALI or the need to deliver vapors vertical to the plane of cells; the recreation of in vivo-present mechanical forces, such as shear stress from vascular flow over endothelial cells; the recapitulation of dynamic intercellular interactions between circulating immune cells and the endothelium; and the ability to maintain in vitro viability and functionality of cells on-chip for several weeks. However, this technology is not without its challenges. It is considered low-throughput and can be costly to establish initially, generally requiring specialized expertise for utilization by those not trained in bioengineering. Consequently, generating data on the toxico-pathology of ENDS aerosols is not as expedient or feasible as might be desired. Furthermore, the model currently lacks certain complexities in lung tissue, such as the sub-epithelial ECM and matrix-embedded stromal cells, which are essential for fully characterizing biological responses. Moreover, physiologically relevant geometries (e.g., cross-sectionally circular microvascular lumens), rather than cross-sectionally rectangular or square-shaped blood vessels, need to be reproduced so that the shear forces of flow are uniformly distrusted across the endothelial barrier99,121. These represent the next frontiers for advancement as the platform continues to evolve.

The Vasculature-on-a-Chip developed by Ohashi et al., while a first step in delineating endothelium-immune cell interactions in the vascular network, has drawbacks that need to be addressed in future studies. For instance, THP-1 cells are a human acute monocytic leukemia cell line and may not accurately reproduce the biology and functioning of either monocytes or macrophages. The utilization of primary immune cells would be more relevant. In addition, multiple donors need to be investigated (from any given population of interest) to map our inter-individual variability. Moreover, it would me physiologically more relevant if in vivo-seen intercellular interactions are simulated. Macrophages are considered innate immune cells that normally reside in peripheral tissues and lymphoid organs122 rather than circulating in the peripheral blood. Thus, the evaluation of innate immune cells such as monocytes and granulocytes with the endothelium would be more relevant. Enhancing the ability of the device to recreate a rounded vascular channel would further emulate in vivo-like features.

Computational and physicochemical analyses of ENDS liquids and aerosols

To better understand the potential health risks associated with ENDS exposure, researchers have also applied in silico modeling alongside physical or chemical characterization of e-liquids and ENDS aerosols123–136. These complementary approaches have provided insights into the composition, behavior, and potential toxicological effects of ENDS products.

Computational fluid-particle dynamics models

Haghnegahdar et al. developed a new multiscale computational fluid-particle dynamics (CFPD)-physiologically based toxicokinetic numerical model to predict local pulmonary deposition and systemic absorption of nicotine and acrolein present in EC aerosols123. This model aimed to elucidate how variations in puff topography could influence the deposition and translocation of these molecules123. Similarly, Zhao et al. employed a CFPD–Pharmacokinetics (PK) model to quantify the deposition of Δ9-tetrahydrocannabinol (THC) particles and vapor absorption in the human upper airways124. Through this computational approach, the authors identified anatomical features and vaping topographic parameters that noticeably impact THC absorption and PK behavior124. While these studies123,124 helped us better understand the effects of anatomical variability on particle deposition and the PK of inhaled cannabis, they lacked explicit benchmarking with human datasets or known toxic compounds. As such, the predictive accuracy of these models has not been fully demonstrated.

In silico toxicity prediction

Other in silico methods have been utilized to predict the cellular toxicity of ENDS constituents. For instance, Kang et al. conducted structural similarity analysis on flavoring chemicals and byproducts found in tobacco products, including ENDS liquids and aerosols, developing a computational model to predict the genotoxicity and mutagenicity of these chemicals125. Similarly, Zarini et al. investigated the applicability of in silico methods for the initial safety assessment of ENDS126. The authors evaluated the potential of quantitative structure-activity relationship (QSAR) models to predict the oral and inhalation toxicity of e-liquid constituents. The study involved screening over 200 compounds via QSAR models. They applied LC50 values (lethal concentration for 50% of the population) to assess the inhalation toxicity of e-liquid ingredients. Specifically, the authors evaluated 28 e-liquid ingredients for rats and 23 for mice. Among these, only 22 and 19 compounds served as training datasets for rats and mice, respectively. The inhalation toxicity potential was studied for only 10 compounds—that is test dataset (6 for rats and 4 for mice). While the study showed a predictability level of 86–88%, there were major limitations to the model used. (1) The primary data for model training and benchmarking were derived from rodent (not human) studies. This poses a challenge as toxicological responses in rodents may not accurately reflect those in humans, potentially leading to less reliable predictions of human health risks. (2) The utilized models relied heavily on LC50 data, which classifies doses on the basis of their lethality potential. This approach necessitates the use of high-dose exposures to determine lethal concentrations, which may not be representative of typical human exposures to e-liquid ingredients. Additionally, LC50 data are often limited and may not be available for all relevant compounds, restricting the model’s applicability and accuracy.

In silico approaches offer solutions to the limitations associated with acquiring high-resolution local dosimetry data on inhaled ENDS aerosols, allowing estimation of the absorption of individual vapor components under various vaping topography profiles and predicting the potential cellular toxicity of e-liquid ingredients when information is scarce. Moreover, these findings support the reduction in and/or replacement of animal usage in preclinical research. However, computational modeling also has major drawbacks. These challenges mainly revolve around data quality, model validation, and the breadth and depth of the parameters that can be modeled. Validation and clinical correlation are essential for establishing the reliability of in silico methods. However, validating particle deposition across different regions of the lung airways or alveoli or analyzing the absorption of individual ENDS vapor components without taking into account a broad range of intermolecular chemical and physical interactions can be extremely challenging. Computational models often have limited input regarding the number and diversity of anatomical features (e.g., upper or lower airways), despite known inter-individual variability. Additionally, researchers may struggle to predict the toxic effects or absorption of e-liquid constituents beyond the respiratory and vascular systems. Emulating certain factors, such as particle charge, hydrophilicity, concentration, interception, thermophoresis, and gas properties, is inherently difficult137. Furthermore, accurately modeling the interactions between inhaled EC aerosol constituents and biological materials such as surfactants remains a complex challenge. Thus, while in silico modeling holds promise for advancing our understanding of ENDS-related health risks, careful validation, and refinement are necessary to ensure the reliability and clinical relevance of the generated data.

Physical and chemical characterization of ENDS aerosols

Several researchers have adopted physical measurements of inhaled particles as a means to predict the potential toxicity of various ENDS products127–132. For instance, Thorne et al. utilized a quartz crystal microbalance (QCM) installed within a smoking machine to quantify the particulate mass deposited from aerosols generated by a cigalike and a closed modular EC127. Additionally, the authors eluted nicotine from the QCM surface for further analysis127. Similarly, Goros et al. employed QCM to analyze the particle dose of ECs containing eight different flavoring chemicals128. In other studies, researchers have utilized cascade impactors for experimental aerosol dosimetry. For example, Oldham et al. determined the particle size distribution from multiple ENDS products using a low-flow cascade impactor129, a strategy also tested by several other research groups130–132. In addition to physical analysis of ENDS aerosols, chemical analytical approaches have been employed to gain insights into the toxicity of emerging vaping products. These methods include nuclear magnetic resonance (NMR) spectroscopy133 and gas chromatography-mass spectrometry (GC-MS)134 on e-liquids and thermal desorption-gas chromatography-time of flight mass spectrometry (TD-GC-TOFMS)135 or ceramic wick136 analysis on ENDS aerosols to identify harmful or potentially harmful constituents.

Despite their advantages, the physicochemical analyses are often performed as terminal endpoints (rather than in real-time) and in the absence of fresh ENDS aerosol generation while simultaneously mimicking the vaping topography and breathing mechanics. Additionally, scaling up such strategies for medium- to high-throughput analysis may pose feasibility challenges. Furthermore, variability between and within experiments may affect the interpretability of the data.

A number of commercially available particle size-analyzing spectrometers exist, including aerodynamic particle sizers (APS), scanning mobility particle sizers (SMPS), and fast mobility particle sizers (FMPS). APS relies on the principle of inertia to size particles, while the SMPS and FMPS utilize the physical principle of electrical mobility, where a particle’s ability to traverse an electric field (its electrical mobility) correlates with its size. SMPS detectors employ condensation particle counters for sensing, whereas FMPS systems utilize multiple low-noise electrometers for particle detection. However, these instruments are not well-positioned for the analysis of ENDS aerosols when the objective is to assess the particle size distribution in real-time while simultaneously replicating the vapor topography and physiological breathing patterns. Thus, there is a clear need for more advanced and capable technologies for the physical characterization of EC aerosols.

Engineered non-living robotic systems for ENDS inhalation toxicology

The field of bioinspired engineering has undergone major advancements, offering innovative solutions across various domains, including toxicological assessment. Bioinspired engineering involves designing systems and devices that mimic the structure and function of biological entities to address complex scientific and engineering challenges. This approach has recently gained traction in the evaluation of ENDS138–141. A notable development in this field has been the development of the Human Vaping Mimetic Real-Time Particle Analyzer (HUMITIPAA) designed by Kaiser et al. 138. This innovative system (see below) exemplifies the potential of bioinspired engineering in toxicological research.

Human vaping mimetic real-time particle analyzer

HUMITIPAA is a biologically inspired, robotic system that integrates laser-based particle detection, the mechanics of respiration, and vaping topography to simulate human vaping behavior. This advanced electro-optical-mechanical system essentially functions as a sensor analogous to one placed at the level of the trachea and is capable of measuring inhaled submicron- and micron-sized particles from EC aerosols in real-time. It operates by mimicking physiological breathing cycles and clinically relevant vaping patterns. The HUMITIPAA categorizes particle size distributions into four ranges—300 nm–1 µm, 1–2.5 µm, 2.5–4 µm, and 4–10 µm—and quantifies the number of particles within each size bracket, as well as providing a cumulative count. Crucially, users can simulate breathing that is clinically evident in both healthy and diseased lung conditions and can adjust vaping topography parameters to reflect different usage patterns. The development of HUMITIPAA was motivated by the sudden emergence of VEA-containing vaping products and the rapid proliferation of e-liquids modified with a wide array of flavorings and other additives, necessitating the need for relevant and practical preclinical tools to evaluate their toxicological profiles. The developers of HUMITIPAA hypothesized that a higher total count of inhaled particles correlates with increased pulmonary toxicity, underscoring the importance of their system in assessing potential health risks associated with vaping products.

Utilizing HUMITIPAA, researchers discovered that even a minimal addition of 1.25% VEA to a 50:50 PG:VG solution resulted in a substantial increase in the number of inhaled particles across all size fractions138. Analysis after seven independent vaping sessions, each comprising nine puffs for a total of 63 puffs, revealed an increase in the cumulative particle count from ~38 million to ~58 million particles per cubic centimeter when the e-liquid contained 5% VEA138. This incorporation of VEA also shifted the size distribution of the inhaled particles. Specifically, there was a slight decrease in the proportion of submicron particles (from 85.4% to 82.2%), while the proportions of particles sized 1–2.5 µm and 2.5–4 µm increased from 12.7% to 15.5% and from 1.6% to 2.0%, respectively138. The researchers postulated that these alterations could in part explain some of the pulmonary pathologies observed in patients with EVALI. Intriguingly, this study also examined the influence of breathing dynamics associated with obstructive (common in asthma and COPD) and restrictive (present in IPF) pulmonary disorders. After correction for volume, the greatest relative increase in the total inhaled particle count was observed with a restrictive breathing pattern (199%), followed by those with obstructive (172%) and healthy (153%) breathing patterns138. This finding suggested that the mechanics and patterns of breathing significantly affect the quantity of particles inhaled. Extrapolating from these findings, one may anticipate that vaping a 5% VEA-supplemented e-liquid could result in increased particle deposition in the respiratory tract of patients with IPF, asthma, or COPD compared with individuals with a healthy breathing profile. Additionally, the introduction of nicotine to e-liquids at concentrations ranging from 0.6% to 2.4% slightly reduced the particle count inhaled, although this effect was not statistically significant and was nullified when VEA was also present in the e-liquid138.

In a subsequent investigation, the same team employed the HUMITIPAA to assess alterations in aerosol particle generation from ECs supplemented with menthol140. Their data indicated that adding 0.1% to 8% menthol to a laboratory-prepared 50:50 PG:VG solution significantly elevated the total number of inhaled particles in a dose-dependent manner. Notably, the study revealed that a commercially and highly popular menthol-flavored EC pod produced considerably more 1–10 µm particles than did a control tobacco pod from the same brand with an equivalent nicotine content140. Crucially, this study corroborated the in vitro HUMITIPAA results with clinical observations. By examining the COPDGene study, which included the most extensive cohort of EC users at that time, a retrospective analysis discerned an association between the use of menthol-flavored ECs and a decrease in key lung function metrics, specifically the FEV1 to forced vital capacity ratio (FEV1/FVC) and the FEV1 as a percentage of the predicted value140. These findings could be pivotal for understanding the respiratory implications of flavored EC use.

The relationships between the size and number of inhaled particles and health risk have been extensively documented in multiple studies142–146. For instance, in a systematic review of over 1900 time-series studies, Ren et al. investigated the relationship between the concentration of PM2.5 particles and daily respiratory deaths in China142. They reported that for every 10 μg/m³ increase in the PM2.5 concentration, a 0.30% increase in daily respiratory deaths occured142. Furthermore, smaller particles (<2.5 µm) are more likely to penetrate deep into the respiratory tract, causing notable health effects. Mathematical calculations, computational fluid dynamics modeling, and epidemiological studies have demonstrated that ultrafine particles (10–250 nm, also commonly referred to as particles <100 nm) have high deposition rates in the alveolar regions of the lung, which increases their potential for adverse health effects143–146.

In the context of VEA added to the PG:VG mixture, research indicates that VEA can degrade at the high temperatures used in vaping devices, producing various toxic compounds such as ketones and aldehydes80,147. Therefore, one can speculate that the negative health effects of VEA in ECs are due to a combination of both increased particle number and the presence of more toxic chemicals resulting from the degradation of VEA, as well as other harmful agents that may be present in VEA-containing e-liquids, such as THC, flavorings, and nicotine.

HUMITIPAA’s future direction and enhancements

The collective findings above underline the applicability of HUMITIPAA as a bioinspired engineered system that facilitates the relatively rapid assessment (within 1–4 days139) of inhaled particle profiles emitted by ECs. Nevertheless, HUMITIPAA requires enhancements in several areas. First, the spectrum of particle size detection must be expanded to include nanoparticles. Despite these technical challenges, it is imperative that advancements in sensor technology be integrated into future versions of HUMITIPAA to capture this critical size range. Second, it is important to establish a clearer association between the biological impact and the increased delivery of particles to pulmonary tissues. Future research should aim to synchronize HUMITIPAA assessments with living biological systems, such as Lung-on-a-Chip. This integration would enable simultaneous acquisition of inhaled particle profiles and exposure of living lung tissue—derived from targeted subject populations—to aerosols from ENDS, thereby facilitating the study of cellular and tissue pathology. Moreover, the incorporation of real-time chemical analysis of EC vapors, in tandem with the physical characterization of the inhaled particle count and size distribution, would greatly enrich the comprehensive evaluation of emerging vaping products. Such advancements would not only refine the precision of toxicological assessments but also bolster the relevance of the findings in the context of public health.

Broader applicability of MPS and robotic systems

MPS and robotic systems hold substantial potential beyond the study of ENDS. These advanced platforms can be instrumental in assessing the health impacts of poor air quality and other inhalation-based risks across wider populations. For instance, Lung-on-a-Chip models can mimic the human lung microenvironment, providing detailed insights into how different pollutants affect lung biology, cellular responses, and tissue functioning. These models have been utilized to study the toxicological effects of various airborne particles, including ultrafine silica nanoparticles and PM2.5 particles148–151, indicating their potential for the study of industrial pollutants, vehicle emissions, and household air contaminants. Furthermore, these systems can be used to identify protective compounds or measures that could mitigate the adverse effects of inhaled pollutants. By integrating MPS and robotic systems with medium-to-high-throughput screening techniques, researchers can systematically test a wide range of compounds to discover those that offer protective benefits. For example, antioxidant compounds or anti-inflammatory agents can be screened for their efficacy in reducing lung inflammation and oxidative stress caused by pollutant exposure. In high-risk living or working environments, such as industrial settings or urban areas with high pollution levels, MPS and robotic systems can be used to evaluate the effectiveness of protective measures. This includes testing the impact of air purification systems, personal protective equipment, and occupational health interventions. By providing precise and human-relevant data, these systems can inform policy decisions and lead to the implementation of more effective strategies to protect public health. Overall, the broader applicability of MPS and robotic systems extends to various fields, offering valuable insights and solutions to improve public health outcomes related to air quality and inhalation risks. These systems not only enhance our understanding of the toxicological impacts of pollutants but also pave the way for discovery of new protective measures and interventions.

Summary and outlook

A thorough analysis of the advent of ENDS reveals critical societal and health-related concerns that are instrumental in shaping both future prospects and potential hurdles within this field. ENDS have catalyzed a substantial shift in nicotine consumption patterns, particularly among adolescents and young adults, mandating a comprehensive understanding of their extensive implications.

The documented toxicity of e-liquid constituents such as PG and VG underscores the imperative for the rigorous assessment of ENDS for pulmonary toxicity. Concurrently, the burgeoning variety of flavorings and chemical compounds in e-liquids complicates the evaluation of their health effects. Unfortunately, the extensive product range and the allure of custom-built e-liquids have propelled their widespread adoption. This calls for the progression of research methodologies and toxicological evaluations to parallel the dynamic evolution of ENDS formulations. The EVALI outbreak in 2019 starkly exemplified the repercussions of insufficient scrutiny of ENDS ingredients, underscoring the difficulty in forecasting health outcomes from innovative and unregulated concoctions. Therefore, there is an urgent need for rapid, comprehensive methods to identify potentially harmful constituents prior to consumer exposure.

Currently, a suite of in vitro, ex vivo, in vivo, and in silico techniques are employed by researchers to examine the toxicological effects of vaping products (Fig. 1, Table 1). These include 2D and 3D static cell cultures, such as TWIs, spheroids and organoids, PCLS, animal models, computational models of pulmonary particle deposition, and physicochemical analytical methods. Nevertheless, the utility of preclinical models is hampered by their limited capacity to replicate the intricate 3D multicellularity of lung tissues, vascular flow, and dynamic intercellular interactions, and they typically have a relatively short lifespan. Moreover, these models cannot introduce ENDS aerosols under conditions that mimic rhythmic breathing without disturbing the natural ALI. Additionally, these strategies often lack high-throughput capabilities. The use of animal models is constrained by considerable interspecies differences that limit extrapolation to humans and ethical concerns. Computational and physicochemical methodologies face challenges related to data quality, model validation, and the limitations inherent in the parameters that can be simulated, as well as the absence of real-time ENDS aerosol generation that emulates actual vaping topography and respiratory mechanics, coupled with a lack of concurrent biological validation.

Emerging Organ-on-Chip technologies and bioinspired robotics, such as the all-primary human Lung Small Airway-on-a-Chip and HUMITIPAA, show promise in addressing certain limitations of traditional approaches and in facilitating human-relevant modeling of lung pathophysiology and relatively rapid toxicity assessments of ENDS aerosols. Nonetheless, these cutting-edge platforms require further technical and biological refinement as they mature. Their deployment and integration into standard practices have the potential to substantially propel the field of inhalation toxicology forward. These represent forthcoming opportunities that can underpin targeted regulations and public health initiatives aimed at curbing the detrimental effects of ENDS.

Globally, discrepancies in the regulation and public perception of ENDS present major challenges. The absence of universal guidelines and the disparate regulatory approaches among nations foster conditions conducive to public health hazards. Consequently, there is a need for global cooperation to formulate uniform regulatory frameworks. The harmonization of policies and the exchange of best practices could act as safeguards against the dissemination of potentially hazardous ENDS products and ensure a unified effort to protect public health.

In summary, while ENDS may potentially offer harm reduction advantages for adult smokers, their widespread appeal to non-smokers, particularly young people, raises substantial public health issues. The future calls for the invention of novel tools and further improvement of current state-of-the-art bioengineered systems that enable scientists to predict the human-relevant pulmonary toxicity of emerging ENDS products more accurately and rapidly, thereby benefiting society and bolstering the efforts of regulatory bodies. Extensive research, progressive policy-making, and international collaboration are essential for adeptly managing the changing milieu of nicotine delivery mechanisms.

Supplementary information

Peer Review File

Supplementary information

The online version contains supplementary material available at 10.1038/s44172-024-00276-3.

Acknowledgements

This work was supported by the Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine at the University of Pittsburgh and National Institutes of Health grants R01HL159494 and U01EB029085. General: Some of the images in Fig. 1, at least in part, were created using BioRender.com.

Author contributions

K.H.B. conceived, drafted, and revised the manuscript.

Peer review

Peer review information

Communications Engineering thanks Hulie Zeng and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Saleem Denholme and Anastasiia Vasylchenkova. A peer review file is available.

Competing interests

K.H.B. is a founder and holds equity in Pneumax, LLC.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Marques, P., Piqueras, L. & Sanz, M.-J. An updated overview of e-cigarette impact on human health. Respir. Res. 22, 10.1186/s12931-021-01737-5 (2021).
2. Lyu, J. C., Huang, P., Jiang, N. & Ling, P. M. A systematic review of E-cigarette marketing communication: messages, communication channels, and strategies. Int. J. Environ. Res. Public Health 19, 9263 (2022).
3. Schraufnagel DE Electronic cigarettes. a position statement of the forum of International Respiratory Societies Am. J. Respir. Crit. Care Med. 2014 190 611 618 10.1164/rccm.201407-1198PP 25006874
Schraufnagel, D. E. et al. Electronic cigarettes. a position statement of the forum of International Respiratory Societies. Am. J. Respir. Crit. Care Med. 190, 611–618 (2014).25006874 10.1164/rccm.201407-1198PP
4. Smith L Brar K Srinivasan K Enja M Lippmann S E-cigarettes: How “safe” are they? J. Fam. Pract. 2016 65 380 385 27474819
Smith, L., Brar, K., Srinivasan, K., Enja, M. & Lippmann, S. E-cigarettes: How “safe” are they? J. Fam. Pract. 65, 380–385 (2016).27474819
5. Gaiha SM Lempert LK Lung H Vescia F Halpern-Felsher B Appealing characteristics of e-cigarette marketing in the retail environment among adolescents Prev. Med. Rep. 2024 43 102769 10.1016/j.pmedr.2024.102769 38883928
Gaiha, S. M., Lempert, L. K., Lung, H., Vescia, F. & Halpern-Felsher, B. Appealing characteristics of e-cigarette marketing in the retail environment among adolescents. Prev. Med. Rep. 43, 102769 (2024).38883928 10.1016/j.pmedr.2024.102769
6. Birdsey J Tobacco product use among U.S. middle and high school students—National Youth Tobacco Survey, 2023 Morbidity Mortal. Wkly. Rep. 2023 72 1173 1182 10.15585/mmwr.mm7244a1
Birdsey, J. et al. Tobacco product use among U.S. middle and high school students—National Youth Tobacco Survey, 2023. Morbidity Mortal. Wkly. Rep. 72, 1173–1182 (2023). Reports a concerning prevalence of tobacco product use among U.S. middle and high school students in 2023, highlighting e-cigarettes as the most commonly used product.10.15585/mmwr.mm7244a1
7. Graham-DeMello A Hoek J Drew J How do underage youth access e-cigarettes in settings with minimum age sales restriction laws? A scoping review BMC Public Health 2023 23 1809 10.1186/s12889-023-16755-9 37723457
Graham-DeMello, A., Hoek, J. & Drew, J. How do underage youth access e-cigarettes in settings with minimum age sales restriction laws? A scoping review. BMC Public Health 23, 1809 (2023).37723457 10.1186/s12889-023-16755-9
8. Shah N Applying topic modelling and qualitative content analysis to identify and characterise ENDS product promotion and sales on Instagram Tob. Control 2023 32 e153 e159 10.1136/tobaccocontrol-2021-056937 34857646
Shah, N. et al. Applying topic modelling and qualitative content analysis to identify and characterise ENDS product promotion and sales on Instagram. Tob. Control 32, e153–e159 (2023).34857646 10.1136/tobaccocontrol-2021-056937
9. Jongenelis MI E-cigarette product preferences of Australian adolescent and adult users: a 2022 study BMC Public Health 2023 23 220 10.1186/s12889-023-15142-8 36726091
Jongenelis, M. I. E-cigarette product preferences of Australian adolescent and adult users: a 2022 study. BMC Public Health 23, 220 (2023).36726091 10.1186/s12889-023-15142-8
10. Riwu Bara RP McCausland K Swanson M Scott L Jancey J They’re sleek, stylish and sexy:” selling e-cigarettes online Aust. N. Z. J. Public Health 2023 47 100013 10.1016/j.anzjph.2022.100013 36641959
Riwu Bara, R. P., McCausland, K., Swanson, M., Scott, L. & Jancey, J. They’re sleek, stylish and sexy:” selling e-cigarettes online. Aust. N. Z. J. Public Health 47, 100013 (2023).36641959 10.1016/j.anzjph.2022.100013
11. Erhabor, J. et al. E-cigarette use among US adults in the 2021 behavioral risk factor surveillance system survey. JAMA Netw Open 6, 10.1001/jamanetworkopen.2023.40859 (2023). Analyzes data from the 2021 Behavioral Risk Factor Surveillance System Survey, revealing patterns and demographic disparities in electronic cigarette use among U.S. adults.
12. Bene-Alhasan Y Electronic nicotine product use is associated with incident heart failure—the all of US research program J. Am. Coll. Cardiol. 2024 83 695 695 10.1016/S0735-1097(24)02685-8 38325995
Bene-Alhasan, Y. et al. Electronic nicotine product use is associated with incident heart failure—the all of US research program. J. Am. Coll. Cardiol. 83, 695–695 (2024).38325995 10.1016/S0735-1097(24)02685-8
13. Mohammadi L Chronic E-cigarette use impairs endothelial function on the physiological and cellular levels Arterioscler Thromb. Vasc. Biol. 2022 42 1333 1350 10.1161/ATVBAHA.121.317749 36288290
Mohammadi, L. et al. Chronic E-cigarette use impairs endothelial function on the physiological and cellular levels. Arterioscler Thromb. Vasc. Biol. 42, 1333–1350 (2022).36288290 10.1161/ATVBAHA.121.317749
14. Tackett AP Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults Thorax 2024 79 163 168 10.1136/thorax-2022-218670 37582630
Tackett, A. P. et al. Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults. Thorax 79, 163–168 (2024).37582630 10.1136/thorax-2022-218670
15. McConnell R Electronic cigarette use and respiratory symptoms in adolescents Am. J. Respir. Crit. Care Med. 2017 195 1043 1049 10.1164/rccm.201604-0804OC 27806211
McConnell, R. et al. Electronic cigarette use and respiratory symptoms in adolescents. Am. J. Respir. Crit. Care Med. 195, 1043–1049 (2017).27806211 10.1164/rccm.201604-0804OC
16. Alnajem A Use of electronic cigarettes and secondhand exposure to their aerosols are associated with asthma symptoms among adolescents: a cross-sectional study Respir. Res. 2020 21 300 10.1186/s12931-020-01569-9 33198741
Alnajem, A. et al. Use of electronic cigarettes and secondhand exposure to their aerosols are associated with asthma symptoms among adolescents: a cross-sectional study. Respir. Res. 21, 300 (2020).33198741 10.1186/s12931-020-01569-9
17. Stefaniak AB Ranpara AC Virji MA LeBouf RF Influence of E-liquid humectants, nicotine, and flavorings on aerosol particle size distribution and implications for modeling respiratory deposition Front. Public Health 2022 10 782068 10.3389/fpubh.2022.782068 35372219
Stefaniak, A. B., Ranpara, A. C., Virji, M. A. & LeBouf, R. F. Influence of E-liquid humectants, nicotine, and flavorings on aerosol particle size distribution and implications for modeling respiratory deposition. Front. Public Health 10, 782068 (2022).35372219 10.3389/fpubh.2022.782068
18. Jensen RP Luo W Pankow JF Strongin RM Peyton DH Hidden formaldehyde in E-cigarette aerosols N. Engl. J. Med. 2015 372 392 394 10.1056/NEJMc1413069 25607446
Jensen, R. P., Luo, W., Pankow, J. F., Strongin, R. M. & Peyton, D. H. Hidden formaldehyde in E-cigarette aerosols. N. Engl. J. Med. 372, 392–394 (2015).25607446 10.1056/NEJMc1413069
19. Azimi, P. et al. An Unrecognized hazard in E-cigarette vapor: preliminary quantification of methylglyoxal formation from propylene glycol in E-cigarettes. Int. J. Environ. Res. Public Health 18, 10.3390/ijerph18020385 (2021).
20. Komura, M. et al. Propylene glycol, a component of electronic cigarette liquid, damages epithelial cells in human small airways. Respir. Res. 23, 10.1186/s12931-022-02142-2 (2022).
21. Sassano MF Evaluation of e-liquid toxicity using an open-source high-throughput screening assay PLoS Biol. 2018 16 e2003904 10.1371/journal.pbio.2003904 29584716
Sassano, M. F. et al. Evaluation of e-liquid toxicity using an open-source high-throughput screening assay. PLoS Biol. 16, e2003904 (2018).29584716 10.1371/journal.pbio.2003904
22. Woodall M E-cigarette constituents propylene glycol and vegetable glycerin decrease glucose uptake and its metabolism in airway epithelial cells in vitro Am. J. Physiol. Lung Cell. Mol. Physiol. 2020 319 L957 L967 10.1152/ajplung.00123.2020 32996783
Woodall, M. et al. E-cigarette constituents propylene glycol and vegetable glycerin decrease glucose uptake and its metabolism in airway epithelial cells in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 319, L957–L967 (2020).32996783 10.1152/ajplung.00123.2020
23. Ghosh A Chronic E-cigarette exposure alters the human bronchial epithelial proteome Am. J. Respir. Crit. Care Med 2018 198 67 76 10.1164/rccm.201710-2033OC 29481290
Ghosh, A. et al. Chronic E-cigarette exposure alters the human bronchial epithelial proteome. Am. J. Respir. Crit. Care Med 198, 67–76 (2018). Demonstrates that chronic exposure to electronic cigarettes significantly alters the proteome of human bronchial epithelial cells, which could contribute to lung disease pathogenesis.29481290 10.1164/rccm.201710-2033OC
24. Burstyn, I. Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health 14, 10.1186/1471-2458-14-18 (2014).
25. Qu Y Szulejko JE Kim K-H Jo S-H The effect of varying battery voltage output on the emission rate of carbonyls released from e-cigarette smoke Microchem. J. 2019 145 47 54 10.1016/j.microc.2018.10.019
Qu, Y., Szulejko, J. E., Kim, K.-H. & Jo, S.-H. The effect of varying battery voltage output on the emission rate of carbonyls released from e-cigarette smoke. Microchem. J. 145, 47–54 (2019).10.1016/j.microc.2018.10.019
26. Schneller LM Vanderbush TS O’Connor RJ Can established vapers distinguish different PG:VG ratios? A pilot study Tob. Regul. Sci. 2018 4 73 78 10.18001/TRS.4.3.6
Schneller, L. M., Vanderbush, T. S., & O’Connor, R. J. Can established vapers distinguish different PG:VG ratios? A pilot study. Tob. Regul. Sci. 4, 73–78 (2018).10.18001/TRS.4.3.6
27. Talih S Characteristics and toxicant emissions of JUUL electronic cigarettes Tob. Control 2019 28 678 680 10.1136/tobaccocontrol-2018-054616 30745326
Talih, S. et al. Characteristics and toxicant emissions of JUUL electronic cigarettes. Tob. Control 28, 678–680 (2019).30745326 10.1136/tobaccocontrol-2018-054616
28. Muthumalage T Inflammatory and oxidative responses induced by exposure to commonly used e-cigarette flavoring chemicals and flavored e-liquids without nicotine Front Physiol. 2017 8 1130 10.3389/fphys.2017.01130 29375399
Muthumalage, T. et al. Inflammatory and oxidative responses induced by exposure to commonly used e-cigarette flavoring chemicals and flavored e-liquids without nicotine. Front Physiol. 8, 1130 (2017).29375399 10.3389/fphys.2017.01130
29. Zhu SH Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation Tob. Control 2014 23 iii3 iii9 10.1136/tobaccocontrol-2014-051670 24935895
Zhu, S. H. et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob. Control 23, iii3–iii9 (2014). Reveals the rapid proliferation of electronic cigarette brands, highlighting the challenges for effective regulation and the need for standardized product oversight.24935895 10.1136/tobaccocontrol-2014-051670
30. Zhang, M. S. et al. Disproportionate use of the ED by patients 3 years after e-cigarette or vaping use-associated lung injury. Chest10.1016/j.chest.2024.02.023 (2024).
31. Jonas AM Raj R Vaping-related acute parenchymal lung injury Chest 2020 158 1555 1565 10.1016/j.chest.2020.03.085 32442559
Jonas, A. M. & Raj, R. Vaping-related acute parenchymal lung injury. Chest 158, 1555–1565 (2020).32442559 10.1016/j.chest.2020.03.085
32. Blount BC Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI N. Engl. J. Med. 2020 382 697 705 10.1056/NEJMoa1916433 31860793
Blount, B. C. et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N. Engl. J. Med. 382, 697–705 (2020). Identify vitamin E acetate in bronchoalveolar-lavage fluid as a key chemical linked to EVALI.31860793 10.1056/NEJMoa1916433
33. CDC. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. <https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html> (2020).
34. Belok SH Parikh R Bernardo J Kathuria H E-cigarette, or vaping, product use-associated lung injury: a review Pneumonia 2020 12 12 10.1186/s41479-020-00075-2 33110741
Belok, S. H., Parikh, R., Bernardo, J. & Kathuria, H. E-cigarette, or vaping, product use-associated lung injury: a review. Pneumonia 12, 12 (2020).33110741 10.1186/s41479-020-00075-2
35. Jonas, A. Impact of vaping on respiratory health. BMJ10.1136/bmj-2021-065997 (2022).
36. Blagev DP Prospectively assessed long-term outcomes of patients with e-cigarette- or vaping-associated lung injury Ann. Am. Thorac. Soc. 2022 19 1892 1899 10.1513/AnnalsATS.202201-049OC 35533314
Blagev, D. P. et al. Prospectively assessed long-term outcomes of patients with e-cigarette- or vaping-associated lung injury. Ann. Am. Thorac. Soc. 19, 1892–1899 (2022).35533314 10.1513/AnnalsATS.202201-049OC
37. Farsalinos KE Kistler KA Gillman G Voudris V Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins Nicotine Tob. Res 2015 17 168 174 10.1093/ntr/ntu176 25180080
Farsalinos, K. E., Kistler, K. A., Gillman, G. & Voudris, V. Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. Nicotine Tob. Res 17, 168–174 (2015).25180080 10.1093/ntr/ntu176
38. CDC. National Institute for Occupational Safety and Health (NIOSH). Criteria for a recommended standard: occupational exposure to diacetyl and 2,3-Pentanedione. <https://www.cdc.gov/niosh/docket/archive/pdfs/NIOSH-245/DraftDiacetylCriteriaDocument081211.pdf> (2011).
39. Chaisson NF Kreiss K Hnizdo E Hakobyan A Enright PL Evaluation of methods to determine excessive decline of forced expiratory volume in one second in workers exposed to diacetyl-containing flavorings J. Occup. Environ. Med. 2010 52 1119 1123 10.1097/JOM.0b013e3181f84577 21063190
Chaisson, N. F., Kreiss, K., Hnizdo, E., Hakobyan, A. & Enright, P. L. Evaluation of methods to determine excessive decline of forced expiratory volume in one second in workers exposed to diacetyl-containing flavorings. J. Occup. Environ. Med. 52, 1119–1123 (2010). Evaluates methods for detecting significant declines in lung function, specifically forced expiratory volume, among workers exposed to diacetyl-containing flavorings, which are known respiratory hazards.21063190 10.1097/JOM.0b013e3181f84577
40. Kanwal R Evaluation of flavorings-related lung disease risk at six microwave popcorn plants J. Occup. Environ. Med. 2006 48 149 157 10.1097/01.jom.0000194152.48728.fb 16474263
Kanwal, R. et al. Evaluation of flavorings-related lung disease risk at six microwave popcorn plants. J. Occup. Environ. Med. 48, 149–157 (2006).16474263 10.1097/01.jom.0000194152.48728.fb
41. From the Centers for Disease Control and Prevention Fixed obstructive lung disease in workers at a microwave popcorn factory-Missouri, 2000-2002 JAMA 2002 287 2939 2940 12052111
From the Centers for Disease Control and Prevention Fixed obstructive lung disease in workers at a microwave popcorn factory-Missouri, 2000-2002. JAMA 287, 2939–2940 (2002).12052111
42. Kreiss K Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant N. Engl. J. Med. 2002 347 330 338 10.1056/NEJMoa020300 12151470
Kreiss, K. et al. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N. Engl. J. Med. 347, 330–338 (2002).12151470 10.1056/NEJMoa020300
43. Klager S Flavoring chemicals and aldehydes in E-cigarette emissions Environ. Sci. Technol. 2017 51 10806 10813 10.1021/acs.est.7b02205 28817267
Klager, S. et al. Flavoring chemicals and aldehydes in E-cigarette emissions. Environ. Sci. Technol. 51, 10806–10813 (2017).28817267 10.1021/acs.est.7b02205
44. Allen JG Flavoring chemicals in e-cigarettes: diacetyl, 2,3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored e-cigarettes Environ. Health Perspect. 2016 124 733 739 10.1289/ehp.1510185 26642857
Allen, J. G. et al. Flavoring chemicals in e-cigarettes: diacetyl, 2,3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored e-cigarettes. Environ. Health Perspect. 124, 733–739 (2016).26642857 10.1289/ehp.1510185
45. WHO. Tobacco: E-cigarettes. <https://www.who.int/news-room/questions-and-answers/item/tobacco-e-cigarettes> (2024).
46. Farsalinos KE Comparison of the cytotoxic potential of cigarette smoke and electronic cigarette vapour extract on cultured myocardial cells Int J. Environ. Res Public Health 2013 10 5146 5162 10.3390/ijerph10105146 24135821
Farsalinos, K. E. et al. Comparison of the cytotoxic potential of cigarette smoke and electronic cigarette vapour extract on cultured myocardial cells. Int J. Environ. Res Public Health 10, 5146–5162 (2013).24135821 10.3390/ijerph10105146
47. Palpant NJ Hofsteen P Pabon L Reinecke H Murry CE Cardiac development in zebrafish and human embryonic stem cells is inhibited by exposure to tobacco cigarettes and e-cigarettes PLoS One 2015 10 e0126259 10.1371/journal.pone.0126259 25978043
Palpant, N. J., Hofsteen, P., Pabon, L., Reinecke, H. & Murry, C. E. Cardiac development in zebrafish and human embryonic stem cells is inhibited by exposure to tobacco cigarettes and e-cigarettes. PLoS One 10, e0126259 (2015).25978043 10.1371/journal.pone.0126259
48. Antoniewicz L Electronic cigarettes increase endothelial progenitor cells in the blood of healthy volunteers Atherosclerosis 2016 255 179 185 10.1016/j.atherosclerosis.2016.09.064 27693003
Antoniewicz, L. et al. Electronic cigarettes increase endothelial progenitor cells in the blood of healthy volunteers. Atherosclerosis 255, 179–185 (2016).27693003 10.1016/j.atherosclerosis.2016.09.064
49. Carnevale R Acute impact of tobacco vs electronic cigarette smoking on oxidative stress and vascular function Chest 2016 150 606 612 10.1016/j.chest.2016.04.012 27108682
Carnevale, R. et al. Acute impact of tobacco vs electronic cigarette smoking on oxidative stress and vascular function. Chest 150, 606–612 (2016).27108682 10.1016/j.chest.2016.04.012
50. Kar Mahapatra S Bhattacharjee S Chakraborty SP Majumdar S Roy S Alteration of immune functions and Th1/Th2 cytokine balance in nicotine-induced murine macrophages: immunomodulatory role of eugenol and N-acetylcysteine Int Immunopharmacol. 2011 11 485 495 10.1016/j.intimp.2010.12.020 21237301
Kar Mahapatra, S., Bhattacharjee, S., Chakraborty, S. P., Majumdar, S. & Roy, S. Alteration of immune functions and Th1/Th2 cytokine balance in nicotine-induced murine macrophages: immunomodulatory role of eugenol and N-acetylcysteine. Int Immunopharmacol. 11, 485–495 (2011).21237301 10.1016/j.intimp.2010.12.020
51. Matsunaga K Klein TW Friedman H Yamamoto Y Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to legionella pneumophila infection by nicotine J. Immunol. 2001 167 6518 6524 10.4049/jimmunol.167.11.6518 11714820
Matsunaga, K., Klein, T. W., Friedman, H. & Yamamoto, Y. Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to legionella pneumophila infection by nicotine. J. Immunol. 167, 6518–6524 (2001).11714820 10.4049/jimmunol.167.11.6518
52. Scott A Pro-inflammatory effects of e-cigarette vapour condensate on human alveolar macrophages Thorax 2018 73 1161 1169 10.1136/thoraxjnl-2018-211663 30104262
Scott, A. et al. Pro-inflammatory effects of e-cigarette vapour condensate on human alveolar macrophages. Thorax 73, 1161–1169 (2018).30104262 10.1136/thoraxjnl-2018-211663
53. Jasper AE E-cigarette vapor renders neutrophils dysfunctional due to filamentous actin accumulation J. Allergy Clin. Immunol. 2024 153 320 329.e328 10.1016/j.jaci.2023.08.025 37678576
Jasper, A. E. et al. E-cigarette vapor renders neutrophils dysfunctional due to filamentous actin accumulation. J. Allergy Clin. Immunol. 153, 320–329.e328 (2024).37678576 10.1016/j.jaci.2023.08.025
54. Antherieu S Comparison of cellular and transcriptomic effects between electronic cigarette vapor and cigarette smoke in human bronchial epithelial cells Toxicol. Vitr. 2017 45 417 425 10.1016/j.tiv.2016.12.015
Antherieu, S. et al. Comparison of cellular and transcriptomic effects between electronic cigarette vapor and cigarette smoke in human bronchial epithelial cells. Toxicol. Vitr. 45, 417–425 (2017).10.1016/j.tiv.2016.12.015
55. Sinha I Evaluating electronic cigarette cytotoxicity and inflammatory responses in vitro Tob. Induc. Dis. 2022 20 45 10.18332/tid/147200 35611070
Sinha, I. et al. Evaluating electronic cigarette cytotoxicity and inflammatory responses in vitro. Tob. Induc. Dis. 20, 45 (2022).35611070 10.18332/tid/147200
56. Manna, V. J., Dwyer, S., Pizutelli, V. & Caradonna, S. J. Utilizing primary human airway mucociliary tissue cultures to model ramifications of chronic E-cigarette usage. Toxicol. In Vitro 94, 10.1016/j.tiv.2023.105725 (2024).
57. Stewart CE Torr EE Mohd Jamili NH Bosquillon C Sayers I Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J Allergy 2012 2012 943982 10.1155/2012/943982
Stewart, C. E., Torr, E. E., Mohd Jamili, N. H., Bosquillon, C. & Sayers, I. Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research.J Allergy 2012, 943982 (2012).10.1155/2012/943982
58. Papaccio, G. et al Human lung epithelial BEAS-2B cells exhibit characteristics of mesenchymal stem cells. Plos ONE 15, 10.1371/journal.pone.0227174 (2020).
59. Lee EM Malson JL Waters AJ Moolchan ET Pickworth WB Smoking topography: reliability and validity in dependent smokers Nicotine Tob. Res. 2003 5 673 679 10.1080/1462220031000158645 14577984
Lee, E. M., Malson, J. L., Waters, A. J., Moolchan, E. T. & Pickworth, W. B. Smoking topography: reliability and validity in dependent smokers. Nicotine Tob. Res. 5, 673–679 (2003).14577984 10.1080/1462220031000158645
60. Strasser AA Pickworth WB Patterson F Lerman C Smoking topography predicts abstinence following treatment with nicotine replacement therapy Cancer Epidemiol. Biomark. Prev. 2004 13 1800 1804 10.1158/1055-9965.1800.13.11
Strasser, A. A., Pickworth, W. B., Patterson, F. & Lerman, C. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol. Biomark. Prev. 13, 1800–1804 (2004).10.1158/1055-9965.1800.13.11
61. Jimenez-Valdes, R. J., Can, U. I., Niemeyer, B. F. & Benam, K. H. Where we stand: lung organotypic living systems that emulate human-relevant host–environment/pathogen interactions. Front. Bioeng. Biotechnol. 8, 10.3389/fbioe.2020.00989 (2020).
62. Saleh F Harb A Soudani N Zaraket H A three-dimensional A549 cell culture model to study respiratory syncytial virus infections J. Infect. Public Health 2020 13 1142 1147 10.1016/j.jiph.2020.03.011 32360024
Saleh, F., Harb, A., Soudani, N. & Zaraket, H. A three-dimensional A549 cell culture model to study respiratory syncytial virus infections. J. Infect. Public Health 13, 1142–1147 (2020).32360024 10.1016/j.jiph.2020.03.011
63. Henry E Adult lung spheroid cells contain progenitor cells and mediate regeneration in rodents with bleomycin-induced pulmonary fibrosis Stem Cells Transl. Med. 2015 4 1265 1274 10.5966/sctm.2015-0062 26359426
Henry, E. et al. Adult lung spheroid cells contain progenitor cells and mediate regeneration in rodents with bleomycin-induced pulmonary fibrosis. Stem Cells Transl. Med. 4, 1265–1274 (2015).26359426 10.5966/sctm.2015-0062
64. Dinh, P.-U. C. et al. Derivation of therapeutic lung spheroid cells from minimally invasive transbronchial pulmonary biopsies. Respir. Res. 18, 10.1186/s12931-017-0611-0 (2017).
65. Pat Y Differentiation of bronchial epithelial spheroids in the presence of IL-13 recapitulates characteristic features of asthmatic airway epithelia Allergy 2022 77 2229 2233 10.1111/all.15279 35266577
Pat, Y. et al. Differentiation of bronchial epithelial spheroids in the presence of IL-13 recapitulates characteristic features of asthmatic airway epithelia. Allergy 77, 2229–2233 (2022).35266577 10.1111/all.15279
66. Ohnishi Y Screening of factors inducing alveolar type 1 epithelial cells using human pluripotent stem cells Stem Cell Rep. 2024 19 529 544 10.1016/j.stemcr.2024.02.009
Ohnishi, Y. et al. Screening of factors inducing alveolar type 1 epithelial cells using human pluripotent stem cells. Stem Cell Rep. 19, 529–544 (2024).10.1016/j.stemcr.2024.02.009
67. Berical A A multimodal iPSC platform for cystic fibrosis drug testing Nat. Commun. 2022 13 4270 10.1038/s41467-022-31854-8 35906215
Berical, A. et al. A multimodal iPSC platform for cystic fibrosis drug testing. Nat. Commun. 13, 4270 (2022).35906215 10.1038/s41467-022-31854-8
68. Dye, B. R. et al. A bioengineered niche promotes in vivo engraftment and maturation of pluripotent stem cell derived human lung organoids. Elife 5, 10.7554/eLife.19732 (2016).
69. Sachs, N. et al. Long‐term expanding human airway organoids for disease modeling. EMBO J. 38, 10.15252/embj.2018100300 (2019).
70. Baarsma HA Epithelial 3D-spheroids as a tool to study air pollutant-induced lung pathology SLAS Discov. 2022 27 185 190 10.1016/j.slasd.2022.02.001 35227934
Baarsma, H. A. et al. Epithelial 3D-spheroids as a tool to study air pollutant-induced lung pathology. SLAS Discov. 27, 185–190 (2022).35227934 10.1016/j.slasd.2022.02.001
71. Alsafadi HN Applications and approaches for three-dimensional precision-cut lung slices. disease modeling and drug discovery Am. J. Respir. Cell Mol. Biol. 2020 62 681 691 10.1165/rcmb.2019-0276TR 31991090
Alsafadi, H. N. et al. Applications and approaches for three-dimensional precision-cut lung slices. disease modeling and drug discovery. Am. J. Respir. Cell Mol. Biol. 62, 681–691 (2020).31991090 10.1165/rcmb.2019-0276TR
72. Viana F O’Kane CM Schroeder GN Precision-cut lung slices: a powerful ex vivo model to investigate respiratory infectious diseases Mol. Microbiol 2022 117 578 588 10.1111/mmi.14817 34570407
Viana, F., O’Kane, C. M. & Schroeder, G. N. Precision-cut lung slices: a powerful ex vivo model to investigate respiratory infectious diseases. Mol. Microbiol 117, 578–588 (2022).34570407 10.1111/mmi.14817
73. Liu G Use of precision cut lung slices as a translational model for the study of lung biology Respir. Res 2019 20 162 10.1186/s12931-019-1131-x 31324219
Liu, G. et al. Use of precision cut lung slices as a translational model for the study of lung biology. Respir. Res 20, 162 (2019).31324219 10.1186/s12931-019-1131-x
74. Michalaki C Dean C Johansson C The use of precision-cut lung slices for studying innate immunity to viral infections Curr. Protoc. 2022 2 e505 10.1002/cpz1.505 35938685
Michalaki, C., Dean, C. & Johansson, C. The use of precision-cut lung slices for studying innate immunity to viral infections. Curr. Protoc. 2, e505 (2022).35938685 10.1002/cpz1.505
75. Crue T Single cell RNA-sequencing of human precision-cut lung slices: A novel approach to study the effect of vaping and viral infection on lung health Innate Immun. 2023 29 61 70 10.1177/17534259231181029 37306239
Crue, T. et al. Single cell RNA-sequencing of human precision-cut lung slices: A novel approach to study the effect of vaping and viral infection on lung health. Innate Immun. 29, 61–70 (2023). Utilizes single-cell RNA-sequencing of human precision-cut lung slices to reveal how electronic cigarette exposure and viral infections uniquely impact lung health at the cellular level.37306239 10.1177/17534259231181029
76. Agraval, H. et al. Electronic cigarette exposure increases the severity of influenza a virus infection via TRAIL dysregulation in human precision-cut lung slices. Int. J. Mol. Sci. 24, 10.3390/ijms24054295 (2023).
77. Silva-Ribeiro T Comparative study of e-cigarette aerosol and cigarette smoke effect on ex vivo embryonic chick lung explants Toxicol. Lett. 2023 376 13 19 10.1016/j.toxlet.2023.01.002 36638931
Silva-Ribeiro, T. et al. Comparative study of e-cigarette aerosol and cigarette smoke effect on ex vivo embryonic chick lung explants. Toxicol. Lett. 376, 13–19 (2023).36638931 10.1016/j.toxlet.2023.01.002
78. Herbert J Kelty JS Laskin JD Laskin DL Gow AJ Menthol flavoring in e-cigarette condensate causes pulmonary dysfunction and cytotoxicity in precision cut lung slices Am. J. Physiol. Lung Cell Mol. Physiol. 2023 324 L345 L357 10.1152/ajplung.00222.2022 36692165
Herbert, J., Kelty, J. S., Laskin, J. D., Laskin, D. L. & Gow, A. J. Menthol flavoring in e-cigarette condensate causes pulmonary dysfunction and cytotoxicity in precision cut lung slices. Am. J. Physiol. Lung Cell Mol. Physiol. 324, L345–L357 (2023).36692165 10.1152/ajplung.00222.2022
79. Ha TN Madison MC Kheradmand F Altman KW Laryngeal inflammatory response to smoke and vape in a murine model Am. J. Otolaryngol. 2019 40 89 92 10.1016/j.amjoto.2018.10.001 30472132
Ha, T. N., Madison, M. C., Kheradmand, F. & Altman, K. W. Laryngeal inflammatory response to smoke and vape in a murine model. Am. J. Otolaryngol. 40, 89–92 (2019).30472132 10.1016/j.amjoto.2018.10.001
80. Bhat TA An animal model of inhaled vitamin E acetate and EVALI-like lung injury N. Engl. J. Med. 2020 382 1175 1177 10.1056/NEJMc2000231 32101656
Bhat, T. A. et al. An animal model of inhaled vitamin E acetate and EVALI-like lung injury. N. Engl. J. Med. 382, 1175–1177 (2020).32101656 10.1056/NEJMc2000231
81. Rau AS Reinikovaite V Schmidt EP Taraseviciene-Stewart L Deleyiannis FW Electronic cigarettes are as toxic to skin flap survival as tobacco cigarettes Ann. Plast. Surg. 2017 79 86 91 10.1097/SAP.0000000000000998 28252546
Rau, A. S., Reinikovaite, V., Schmidt, E. P., Taraseviciene-Stewart, L. & Deleyiannis, F. W. Electronic cigarettes are as toxic to skin flap survival as tobacco cigarettes. Ann. Plast. Surg. 79, 86–91 (2017).28252546 10.1097/SAP.0000000000000998
82. Rasmussen LW Stanford D LaFontaine J Allen AD Raju SV Nicotine aerosols diminish airway CFTR function and mucociliary clearance Am. J. Physiol. Lung Cell Mol. Physiol. 2023 324 L557 L570 10.1152/ajplung.00453.2021 36852921
Rasmussen, L. W., Stanford, D., LaFontaine, J., Allen, A. D. & Raju, S. V. Nicotine aerosols diminish airway CFTR function and mucociliary clearance. Am. J. Physiol. Lung Cell Mol. Physiol. 324, L557–L570 (2023). Demonstrates that exposure to nicotine aerosols impairs airway CFTR function and reduces mucociliary clearance, which are critical processes for maintaining respiratory health, potentially increasing the risk of lung disease.36852921 10.1152/ajplung.00453.2021
83. Kim MD The combination of propylene glycol and vegetable glycerin e-cigarette aerosols induces airway inflammation and mucus hyperconcentration Sci. Rep. 2024 14 1942 10.1038/s41598-024-52317-8 38253598
Kim, M. D. et al. The combination of propylene glycol and vegetable glycerin e-cigarette aerosols induces airway inflammation and mucus hyperconcentration. Sci. Rep. 14, 1942 (2024).38253598 10.1038/s41598-024-52317-8
84. Hyde DM Hamid Q Irvin CG Anatomy, pathology, and physiology of the tracheobronchial tree: emphasis on the distal airways J. Allergy Clin. Immunol. 2009 124 S72 S77 10.1016/j.jaci.2009.08.048 19962039
Hyde, D. M., Hamid, Q. & Irvin, C. G. Anatomy, pathology, and physiology of the tracheobronchial tree: emphasis on the distal airways. J. Allergy Clin. Immunol. 124, S72–S77 (2009).19962039 10.1016/j.jaci.2009.08.048
85. Kolaczkowska E Kubes P Neutrophil recruitment and function in health and inflammation Nat. Rev. Immunol. 2013 13 159 175 10.1038/nri3399 23435331
Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159–175 (2013).23435331 10.1038/nri3399
86. Wright JL Cosio M Churg A Animal models of chronic obstructive pulmonary disease Am. J. Physiol. Lung Cell. Mol. Physiol. 2008 295 L1 L15 10.1152/ajplung.90200.2008 18456796
Wright, J. L., Cosio, M. & Churg, A. Animal models of chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L1–L15 (2008).18456796 10.1152/ajplung.90200.2008
87. Benam KH Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro Nat. Methods 2016 13 151 157 10.1038/nmeth.3697 26689262
Benam, K. H. et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat. Methods 13, 151–157 (2016). Introduces the Small Airway-on-a-Chip, a state-of-the-art in vitro model that replicates human lung inflammation and drug responses, providing a powerful platform for studying respiratory diseases and potential therapeutic interventions.26689262 10.1038/nmeth.3697
88. Hecht SS Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new Carcinogenesis 2005 26 1488 1492 10.1093/carcin/bgi148 15930027
Hecht, S. S. Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis 26, 1488–1492 (2005). Reviews the development and application of engineered in vitro disease models, emphasizing their potential to enhance our understanding of disease mechanisms and improve therapeutic discovery.15930027 10.1093/carcin/bgi148
89. Benam KH Engineered in vitro disease models Annu Rev. Pathol. 2015 10 195 262 10.1146/annurev-pathol-012414-040418 25621660
Benam, K. H. et al. Engineered in vitro disease models. Annu Rev. Pathol. 10, 195–262 (2015).25621660 10.1146/annurev-pathol-012414-040418
90. Benam KH Ingber DE Commendation for exposing key advantage of organ chip approach Cell Syst. 2016 3 411 10.1016/j.cels.2016.11.009 27883885
Benam, K. H. & Ingber, D. E. Commendation for exposing key advantage of organ chip approach. Cell Syst. 3, 411 (2016).27883885 10.1016/j.cels.2016.11.009
91. Benam KH Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip Cell Syst. 2016 3 456 466.e454 10.1016/j.cels.2016.10.003 27894999
Benam, K. H. et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 3, 456–466.e454 (2016). Demonstrates application of a microengineered breathing Lung Chip to model and compare normal and diseased human airway responses, providing insights into the pathophysiology of respiratory diseases.27894999 10.1016/j.cels.2016.10.003
92. Benam KH Human lung small airway-on-a-chip protocol Methods Mol. Biol. 2017 1612 345 365 10.1007/978-1-4939-7021-6_25 28634955
Benam, K. H. et al. Human lung small airway-on-a-chip protocol. Methods Mol. Biol. 1612, 345–365 (2017).28634955 10.1007/978-1-4939-7021-6_25
93. Benam KH Konigshoff M Eickelberg O Breaking the in vitro barrier in respiratory medicine. engineered microphysiological systems for chronic obstructive pulmonary disease and beyond Am. J. Respir. Crit. Care Med. 2018 197 869 875 10.1164/rccm.201709-1795PP 29262260
Benam, K. H., Konigshoff, M. & Eickelberg, O. Breaking the in vitro barrier in respiratory medicine. engineered microphysiological systems for chronic obstructive pulmonary disease and beyond. Am. J. Respir. Crit. Care Med. 197, 869–875 (2018).29262260 10.1164/rccm.201709-1795PP
94. Niemeyer BF Zhao P Tuder RM Benam KH Advanced microengineered lung models for translational drug discovery SLAS Discov. 2018 23 777 789 10.1177/2472555218760217 29447055
Niemeyer, B. F., Zhao, P., Tuder, R. M. & Benam, K. H. Advanced microengineered lung models for translational drug discovery. SLAS Discov. 23, 777–789 (2018).29447055 10.1177/2472555218760217
95. Benam KH Exploring new technologies in biomedical research Drug Discov. Today 2019 24 1242 1247 10.1016/j.drudis.2019.04.001 30953865
Benam, K. H. et al. Exploring new technologies in biomedical research. Drug Discov. Today 24, 1242–1247 (2019).30953865 10.1016/j.drudis.2019.04.001
96. Benam KH Novak R Ferrante TC Choe Y Ingber DE Biomimetic smoking robot for in vitro inhalation exposure compatible with microfluidic organ chips Nat. Protoc. 2020 15 183 206 10.1038/s41596-019-0230-y 31925401
Benam, K. H., Novak, R., Ferrante, T. C., Choe, Y. & Ingber, D. E. Biomimetic smoking robot for in vitro inhalation exposure compatible with microfluidic organ chips. Nat. Protoc. 15, 183–206 (2020). Describes the development and application of a biomimetic smoking robot designed for in vitro inhalation exposure studies using microfluidic Organs-on-Chips, providing a more accurate method to assess the impact of smoking on human lung health.31925401 10.1038/s41596-019-0230-y
97. Jimenez-Valdes RJ Can UI Niemeyer BF Benam KH Where we stand: lung organotypic living systems that emulate human-relevant host-environment/pathogen interactions Front. Bioeng. Biotechnol. 2020 8 989 10.3389/fbioe.2020.00989 32903497
Jimenez-Valdes, R. J., Can, U. I., Niemeyer, B. F. & Benam, K. H. Where we stand: lung organotypic living systems that emulate human-relevant host-environment/pathogen interactions. Front. Bioeng. Biotechnol. 8, 989 (2020).32903497 10.3389/fbioe.2020.00989
98. Benam KH Burgess JK Stewart AG Editorial: accelerated translation using microphysiological organoid and microfluidic chip models Front. Pharm. 2021 12 827172 10.3389/fphar.2021.827172
Benam, K. H., Burgess, J. K. & Stewart, A. G. Editorial: accelerated translation using microphysiological organoid and microfluidic chip models. Front. Pharm. 12, 827172 (2021).10.3389/fphar.2021.827172
99. Vo Q Benam KH Advancements in preclinical human-relevant modeling of pulmonary vasculature on-chip Eur. J. Pharm. Sci. 2024 195 106709 10.1016/j.ejps.2024.106709 38246431
Vo, Q. & Benam, K. H. Advancements in preclinical human-relevant modeling of pulmonary vasculature on-chip. Eur. J. Pharm. Sci. 195, 106709 (2024).38246431 10.1016/j.ejps.2024.106709
100. Benam KH Disrupting experimental strategies for inhalation toxicology: the emergence of microengineered breathing-smoking human lung-on-a-chip Appl. Vitr. Toxicol. 2018 4 107 114 10.1089/aivt.2017.0030
Benam, K. H. Disrupting experimental strategies for inhalation toxicology: the emergence of microengineered breathing-smoking human lung-on-a-chip. Appl. Vitr. Toxicol. 4, 107–114 (2018).10.1089/aivt.2017.0030
101. Hajipouran Benam, K. et al. Human small airway-on-a-chip: A novel microphysiological system to model lung inflammation, accelerate drug development and enable inhalational toxico-analysis. in 5.1 Airway Pharmacology and Treatment10.1183/13993003.congress-2016.OA4542 (2016).
102. Si L A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics Nat. Biomed. Eng. 2021 5 815 829 10.1038/s41551-021-00718-9 33941899
Si, L. et al. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat. Biomed. Eng. 5, 815–829 (2021).33941899 10.1038/s41551-021-00718-9
103. Ohashi K Hayashida A Nozawa A Matsumura K Ito S Human vasculature-on-a-chip with macrophage-mediated endothelial activation: The biological effect of aerosol from heated tobacco products on monocyte adhesion Toxicol. Vitr. 2023 89 105582 10.1016/j.tiv.2023.105582
Ohashi, K., Hayashida, A., Nozawa, A., Matsumura, K. & Ito, S. Human vasculature-on-a-chip with macrophage-mediated endothelial activation: The biological effect of aerosol from heated tobacco products on monocyte adhesion. Toxicol. Vitr. 89, 105582 (2023).10.1016/j.tiv.2023.105582
104. Jang, K. J. et al. Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci. Transl. Med. 11, 10.1126/scitranslmed.aax5516 (2019).
105. Ewart, L. et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun. Med. 2, 10.1038/s43856-022-00209-1 (2022).
106. Steinberg E A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine Commun. Biol. 2023 6 1157 10.1038/s42003-023-05531-5 37957280
Steinberg, E. et al. A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine. Commun. Biol. 6, 1157 (2023).37957280 10.1038/s42003-023-05531-5
107. Hassell BA Human organ chip models recapitulate orthotopic lung cancer growth, therapeutic responses, and tumor dormancy in vitro Cell Rep. 2017 21 508 516 10.1016/j.celrep.2017.09.043 29020635
Hassell, B. A. et al. Human organ chip models recapitulate orthotopic lung cancer growth, therapeutic responses, and tumor dormancy in vitro. Cell Rep. 21, 508–516 (2017).29020635 10.1016/j.celrep.2017.09.043
108. Carvalho, D. J. et al. Thyroid‐on‐a‐Chip: an organoid platform for in vitro assessment of endocrine disruption. Adv. Healthcare Mater. 12, 10.1002/adhm.202201555 (2023).
109. Mehta V Vilikkathala Sudhakaran S Nellore V Madduri S Rath SN 3D stem-like spheroids-on-a-chip for personalized combinatorial drug testing in oral cancer J. Nanobiotechnol. 2024 22 344 10.1186/s12951-024-02625-y
Mehta, V., Vilikkathala Sudhakaran, S., Nellore, V., Madduri, S. & Rath, S. N. 3D stem-like spheroids-on-a-chip for personalized combinatorial drug testing in oral cancer. J. Nanobiotechnol. 22, 344 (2024).10.1186/s12951-024-02625-y
110. Jeibouei S Human-derived Tumor-On-Chip model to study the heterogeneity of breast cancer tissue Biomater. Adv. 2024 162 213915 10.1016/j.bioadv.2024.213915 38878646
Jeibouei, S. et al. Human-derived Tumor-On-Chip model to study the heterogeneity of breast cancer tissue. Biomater. Adv. 162, 213915 (2024).38878646 10.1016/j.bioadv.2024.213915
111. Park J Three-dimensional brain-on-a-chip with an interstitial level of flow and its application as an in vitro model of Alzheimer’s disease Lab Chip 2015 15 141 150 10.1039/C4LC00962B 25317977
Park, J. et al. Three-dimensional brain-on-a-chip with an interstitial level of flow and its application as an in vitro model of Alzheimer’s disease. Lab Chip 15, 141–150 (2015).25317977 10.1039/C4LC00962B
112. Katsikoudi A Quantitative propagation of assembled human Tau from Alzheimer’s disease brain in microfluidic neuronal cultures J. Biol. Chem. 2020 295 13079 13093 10.1074/jbc.RA120.013325 32699110
Katsikoudi, A. et al. Quantitative propagation of assembled human Tau from Alzheimer’s disease brain in microfluidic neuronal cultures. J. Biol. Chem. 295, 13079–13093 (2020).32699110 10.1074/jbc.RA120.013325
113. Schreiner, T. G., Creangă-Murariu, I., Tamba, B. I., Lucanu, N. & Popescu, B. O. In vitro modeling of the blood–brain barrier for the study of physiological conditions and Alzheimer’s disease. Biomolecules 12, 10.3390/biom12081136 (2022).
114. Park TE Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies Nat. Commun. 2019 10 2621 10.1038/s41467-019-10588-0 31197168
Park, T. E. et al. Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies. Nat. Commun. 10, 2621 (2019).31197168 10.1038/s41467-019-10588-0
115. Pediaditakis, I. et al. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nat. Commun. 12, 10.1038/s41467-021-26066-5 (2021).
116. Fiore, N. J. et al. Bioengineered models of Parkinson’s disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment. Cell. Mol. Life Sci. 79, 10.1007/s00018-021-04047-7 (2022).
117. Marsano A Beating heart on a chip: a novel microfluidic platform to generate functional 3D cardiac microtissues Lab Chip 2016 16 599 610 10.1039/C5LC01356A 26758922
Marsano, A. et al. Beating heart on a chip: a novel microfluidic platform to generate functional 3D cardiac microtissues. Lab Chip 16, 599–610 (2016).26758922 10.1039/C5LC01356A
118. Oleaga C Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system Biomaterials 2018 182 176 190 10.1016/j.biomaterials.2018.07.062 30130706
Oleaga, C. et al. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system. Biomaterials 182, 176–190 (2018).30130706 10.1016/j.biomaterials.2018.07.062
119. Yadid, M. et al. Endothelial extracellular vesicles contain protective proteins and rescue ischemia-reperfusion injury in a human heart-on-chip. Sci. Transl. Med. 12, 10.1126/scitranslmed.aax8005 (2020).
120. Lind JU Cardiac microphysiological devices with flexible thin-film sensors for higher-throughput drug screening Lab Chip 2017 17 3692 3703 10.1039/C7LC00740J 28976521
Lind, J. U. et al. Cardiac microphysiological devices with flexible thin-film sensors for higher-throughput drug screening. Lab Chip 17, 3692–3703 (2017).28976521 10.1039/C7LC00740J
121. Vo, Q. et al. On‐chip reconstitution of uniformly shear‐sensing 3D matrix‐embedded multicellular blood microvessel. Adv. Funct. Mater., 34, 2304630 (2023).
122. Sender, R. et al. The total mass, number, and distribution of immune cells in the human body. Proc. Natl Acad. Sci. 120, 10.1073/pnas.2308511120 (2023).
123. Haghnegahdar A Feng Y Chen X Lin J Computational analysis of deposition and translocation of inhaled nicotine and acrolein in the human body with e-cigarette puffing topographies Aerosol Sci. Technol. 2018 52 483 493 10.1080/02786826.2018.1447644 30381781
Haghnegahdar, A., Feng, Y., Chen, X. & Lin, J. Computational analysis of deposition and translocation of inhaled nicotine and acrolein in the human body with e-cigarette puffing topographies. Aerosol Sci. Technol. 52, 483–493 (2018).30381781 10.1080/02786826.2018.1447644
124. Zhao J Feng Y Tian G Taylor C Arden NS Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study Comput. Biol. Med. 2021 132 104333 10.1016/j.compbiomed.2021.104333 33770654
Zhao, J., Feng, Y., Tian, G., Taylor, C. & Arden, N. S. Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study. Comput. Biol. Med. 132, 104333 (2021).33770654 10.1016/j.compbiomed.2021.104333
125. Kang JC Valerio LG Jr Investigating DNA adduct formation by flavor chemicals and tobacco byproducts in electronic nicotine delivery system (ENDS) using in silico approaches Toxicol. Appl Pharm. 2020 398 115026 10.1016/j.taap.2020.115026
Kang, J. C. & Valerio, L. G. Jr Investigating DNA adduct formation by flavor chemicals and tobacco byproducts in electronic nicotine delivery system (ENDS) using in silico approaches. Toxicol. Appl Pharm. 398, 115026 (2020).10.1016/j.taap.2020.115026
126. Zarini D Are in silico approaches applicable as a first step for the prediction of e-liquid toxicity in e-cigarettes? Chem. Res. Toxicol. 2020 33 2381 2389 10.1021/acs.chemrestox.0c00136 32786541
Zarini, D. et al. Are in silico approaches applicable as a first step for the prediction of e-liquid toxicity in e-cigarettes? Chem. Res. Toxicol. 33, 2381–2389 (2020).32786541 10.1021/acs.chemrestox.0c00136
127. Thorne D Larard S Baxter A Meredith C Gaҫa M The comparative in vitro assessment of e-cigarette and cigarette smoke aerosols using the gammaH2AX assay and applied dose measurements Toxicol. Lett. 2017 265 170 178 10.1016/j.toxlet.2016.12.006 27965004
Thorne, D., Larard, S., Baxter, A., Meredith, C. & Gaҫa, M. The comparative in vitro assessment of e-cigarette and cigarette smoke aerosols using the gammaH2AX assay and applied dose measurements. Toxicol. Lett. 265, 170–178 (2017).27965004 10.1016/j.toxlet.2016.12.006
128. Goros RA Xu X Li G Zuo YY Adverse biophysical impact of e-cigarette flavors on pulmonary surfactant Environ. Sci. Technol. 2023 57 15882 15891 10.1021/acs.est.3c05896 37824199
Goros, R. A., Xu, X., Li, G. & Zuo, Y. Y. Adverse biophysical impact of e-cigarette flavors on pulmonary surfactant. Environ. Sci. Technol. 57, 15882–15891 (2023).37824199 10.1021/acs.est.3c05896
129. Oldham MJ Zhang J Rusyniak MJ Kane DB Gardner WP Particle size distribution of selected electronic nicotine delivery system products Food Chem. Toxicol. 2018 113 236 240 10.1016/j.fct.2018.01.045 29408542
Oldham, M. J., Zhang, J., Rusyniak, M. J., Kane, D. B. & Gardner, W. P. Particle size distribution of selected electronic nicotine delivery system products. Food Chem. Toxicol. 113, 236–240 (2018).29408542 10.1016/j.fct.2018.01.045
130. Ranpara A Stefaniak AB Williams K Fernandez E LeBouf RF Modeled respiratory tract deposition of aerosolized oil diluents used in delta(9)-THC-based electronic cigarette liquid products Front. Public Health 2021 9 744166 10.3389/fpubh.2021.744166 34805068
Ranpara, A., Stefaniak, A. B., Williams, K., Fernandez, E. & LeBouf, R. F. Modeled respiratory tract deposition of aerosolized oil diluents used in delta(9)-THC-based electronic cigarette liquid products. Front. Public Health 9, 744166 (2021).34805068 10.3389/fpubh.2021.744166
131. Ranpara A Stefaniak AB Fernandez E LeBouf RF Effect of puffing behavior on particle size distributions and respiratory depositions from pod-style electronic cigarette, or vaping, products Front. Public Health 2021 9 750402 10.3389/fpubh.2021.750402 34926374
Ranpara, A., Stefaniak, A. B., Fernandez, E. & LeBouf, R. F. Effect of puffing behavior on particle size distributions and respiratory depositions from pod-style electronic cigarette, or vaping, products. Front. Public Health 9, 750402 (2021).34926374 10.3389/fpubh.2021.750402
132. Lalo H Leclerc L Sorin J Pourchez J Aerosol droplet-size distribution and airborne nicotine portioning in particle and gas phases emitted by electronic cigarettes Sci. Rep. 2020 10 21707 10.1038/s41598-020-78749-6 33303941
Lalo, H., Leclerc, L., Sorin, J. & Pourchez, J. Aerosol droplet-size distribution and airborne nicotine portioning in particle and gas phases emitted by electronic cigarettes. Sci. Rep. 10, 21707 (2020).33303941 10.1038/s41598-020-78749-6
133. Hahn J Electronic cigarettes: overview of chemical composition and exposure estimation Tob. Induc. Dis. 2014 12 23 10.1186/s12971-014-0023-6 25620905
Hahn, J. et al. Electronic cigarettes: overview of chemical composition and exposure estimation. Tob. Induc. Dis. 12, 23 (2014).25620905 10.1186/s12971-014-0023-6
134. Krusemann EJZ GC-MS analysis of e-cigarette refill solutions: a comparison of flavoring composition between flavor categories J. Pharm. Biomed. Anal. 2020 188 113364 10.1016/j.jpba.2020.113364 32512254
Krusemann, E. J. Z. et al. GC-MS analysis of e-cigarette refill solutions: a comparison of flavoring composition between flavor categories. J. Pharm. Biomed. Anal. 188, 113364 (2020).32512254 10.1016/j.jpba.2020.113364
135. Rawlinson C Martin S Frosina J Wright C Chemical characterisation of aerosols emitted by electronic cigarettes using thermal desorption-gas chromatography-time of flight mass spectrometry J. Chromatogr. A 2017 1497 144 154 10.1016/j.chroma.2017.02.050 28381359
Rawlinson, C., Martin, S., Frosina, J. & Wright, C. Chemical characterisation of aerosols emitted by electronic cigarettes using thermal desorption-gas chromatography-time of flight mass spectrometry. J. Chromatogr. A 1497, 144–154 (2017).28381359 10.1016/j.chroma.2017.02.050
136. Pinto MI Chemical characterisation of the vapour emitted by an e-cigarette using a ceramic wick-based technology Sci. Rep. 2022 12 16497 10.1038/s41598-022-19761-w 36192548
Pinto, M. I. et al. Chemical characterisation of the vapour emitted by an e-cigarette using a ceramic wick-based technology. Sci. Rep. 12, 16497 (2022).36192548 10.1038/s41598-022-19761-w
137. Frohlich E Salar-Behzadi S Toxicological assessment of inhaled nanoparticles: role of in vivo, ex vivo, in vitro, and in silico studies Int J. Mol. Sci. 2014 15 4795 4822 10.3390/ijms15034795 24646916
Frohlich, E. & Salar-Behzadi, S. Toxicological assessment of inhaled nanoparticles: role of in vivo, ex vivo, in vitro, and in silico studies. Int J. Mol. Sci. 15, 4795–4822 (2014).24646916 10.3390/ijms15034795
138. Kaiser AJ A robotic system for real-time analysis of inhaled submicron and microparticles iScience 2021 24 103091 10.1016/j.isci.2021.103091 34755082
Kaiser, A. J. et al. A robotic system for real-time analysis of inhaled submicron and microparticles. iScience 24, 103091 (2021). Reports development of a robotic system that enables real-time analysis of inhaled submicron and microparticles, advancing the study of respiratory exposure to inhaled particulate matter from tobacco products including electronic cigarettes.34755082 10.1016/j.isci.2021.103091
139. Bogdanoff RF Kaiser AJ Benam KH Protocol for the operation of a breathing and vaping biomimetic robot to delineate real-time inhaled particle profile of electronic cigarettes STAR Protoc. 2022 3 101885 10.1016/j.xpro.2022.101885 36595946
Bogdanoff, R. F., Kaiser, A. J. & Benam, K. H. Protocol for the operation of a breathing and vaping biomimetic robot to delineate real-time inhaled particle profile of electronic cigarettes. STAR Protoc. 3, 101885 (2022).36595946 10.1016/j.xpro.2022.101885
140. Chandra D Bogdanoff RF Bowler RP Benam KH Electronic cigarette menthol flavoring is associated with increased inhaled micro and sub-micron particles and worse lung function in combustion cigarette smokers Respir. Res 2023 24 108 10.1186/s12931-023-02410-9 37038183
Chandra, D., Bogdanoff, R. F., Bowler, R. P. & Benam, K. H. Electronic cigarette menthol flavoring is associated with increased inhaled micro and sub-micron particles and worse lung function in combustion cigarette smokers. Respir. Res 24, 108 (2023). Demonstrates that electronic cigarette menthol flavoring is linked to increased inhalation of micro and sub-micron particles and worsened lung function in smokers of combustion cigarettes.37038183 10.1186/s12931-023-02410-9
141. This robot vapes for science. Nature 598, 11–11 10.1038/d41586-021-02679-0 (2021).
142. Ren M Concentration-response relationship between PM2.5 and daily respiratory deaths in China: a systematic review and metaregression analysis of time-series studies BioMed. Res. Int. 2017 2017 1 15
Ren, M. et al. Concentration-response relationship between PM2.5 and daily respiratory deaths in China: a systematic review and metaregression analysis of time-series studies. BioMed. Res. Int. 2017, 1–15 (2017).
143. Hammer T Gao H Pan Z Wang J Relationship between aerosols exposure and lung deposition dose Aerosol Air Qual. Res. 2020 20 1083 1093 10.4209/aaqr.2020.01.0033
Hammer, T., Gao, H., Pan, Z. & Wang, J. Relationship between aerosols exposure and lung deposition dose. Aerosol Air Qual. Res. 20, 1083–1093 (2020).10.4209/aaqr.2020.01.0033
144. Ou C Hang J Deng Q Particle deposition in human lung airways: effects of airflow, particle size, and mechanisms Aerosol Air Qual. Res. 2020 20 2846 2858 10.4209/aaqr.2020.02.0067
Ou, C., Hang, J. & Deng, Q. Particle deposition in human lung airways: effects of airflow, particle size, and mechanisms. Aerosol Air Qual. Res. 20, 2846–2858 (2020).10.4209/aaqr.2020.02.0067
145. Yan R Associations between ultrafine particle pollution and daily outpatient visits for respiratory diseases in Shanghai, China: a time-series analysis Environ. Sci. Pollut. Res. 2023 31 3004 3013 10.1007/s11356-023-31248-3
Yan, R. et al. Associations between ultrafine particle pollution and daily outpatient visits for respiratory diseases in Shanghai, China: a time-series analysis. Environ. Sci. Pollut. Res. 31, 3004–3013 (2023).10.1007/s11356-023-31248-3
146. Ohlwein S Kappeler R Kutlar Joss M Künzli N Hoffmann B Health effects of ultrafine particles: a systematic literature review update of epidemiological evidence Int. J. Public Health 2019 64 547 559 10.1007/s00038-019-01202-7 30790006
Ohlwein, S., Kappeler, R., Kutlar Joss, M., Künzli, N. & Hoffmann, B. Health effects of ultrafine particles: a systematic literature review update of epidemiological evidence. Int. J. Public Health 64, 547–559 (2019).30790006 10.1007/s00038-019-01202-7
147. LeBouf, R. F. et al. Chemical emissions from heated vitamin e acetate—insights to respiratory risks from electronic cigarette liquid oil diluents used in the aerosolization of Δ9-THC-containing products. Front. Public Health 9, 10.3389/fpubh.2021.765168 (2022).
148. Huh D Reconstituting organ-level lung functions on a chip Science 2010 328 1662 1668 10.1126/science.1188302 20576885
Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668 (2010).20576885 10.1126/science.1188302
149. Zheng L An air–liquid interface organ-level lung microfluidics platform for analysis on molecular mechanisms of cytotoxicity induced by cancer-causing fine particles ACS Sens. 2019 4 907 917 10.1021/acssensors.8b01672 30843693
Zheng, L. et al. An air–liquid interface organ-level lung microfluidics platform for analysis on molecular mechanisms of cytotoxicity induced by cancer-causing fine particles. ACS Sens. 4, 907–917 (2019).30843693 10.1021/acssensors.8b01672
150. Xu C Assessment of air pollutant PM2.5 pulmonary exposure using a 3D lung-on-chip model ACS Biomater. Sci. Eng. 2020 6 3081 3090 10.1021/acsbiomaterials.0c00221 33463279
Xu, C. et al. Assessment of air pollutant PM2.5 pulmonary exposure using a 3D lung-on-chip model. ACS Biomater. Sci. Eng. 6, 3081–3090 (2020).33463279 10.1021/acsbiomaterials.0c00221
151. Guan, M. et al. Development of alveolar-capillary-exchange (ACE) chip and its application for assessment of PM2.5-induced toxicity. Ecotoxicol. Environ. Saf. 223, 10.1016/j.ecoenv.2021.112601 (2021).
